

**EXCELSIOR MEDICAL CO., LTD.
AND SUBSIDIARIES**

CONSOLIDATED FINANCIAL STATEMENTS

**With Independent Auditors' Review Report
For the Six Months Ended June 30, 2026 and 2025**

**Address: 17F., No.880, Zhongzheng Rd., Zhonghe Dist., New Taipei City 235,
Taiwan, R.O.C.**
Telephone: (02)22251888

The independent auditors' review report and the accompanying consolidated financial statements are the English translation of the Chinese version prepared and used in the Republic of China. If there is any conflict between, or any difference in the interpretation of the English and Chinese language independent auditors' review report and consolidated financial statements, the Chinese version shall prevail.

Table of contents

Contents	Page
1. Cover Page	1
2. Table of Contents	2
3. Independent Auditors' Review Report	3
4. Consolidated Balance Sheets	4
5. Consolidated Statements of Comprehensive Income	5
6. Consolidated Statements of Changes in Equity	6
7. Consolidated Statements of Cash Flows	7
8. Notes to the Consolidated Financial Statements	
(1)Company History	8
(2)Financial Statements Authorization Date and Authorization Process	8
(3)New Standards, Amendments and Interpretations Adopted	8~10
(4)Summary of material accounting policies	10~13
(5)Significant Accounting Assumptions and Judgments, and Major Sources of Estimation Uncertainty	13
(6)Explanation of Significant Accounts	14~51
(7)Related Party Transactions	52~57
(8)Pledged Assets	57
(9)Significant Commitments and Contingencies	58
(10)Losses due to Major Disasters	58
(11)Subsequent Events	58
(12)Other	58
(13)Other disclosures	
(a) Information on significant transactions	59~61
(b) Information on investees	61~63
(c) Information on investment in mainland China	63~64
(14)Segment Information	64~65



安侯建業聯合會計師事務所
KPMG

台北市110615信義路5段7號68樓(台北101大樓)
68F., TAIPEI 101 TOWER, No. 7, Sec. 5,
Xinyi Road, Taipei City 110615, Taiwan (R.O.C.)

電 話 Tel	+ 886 2 8101 6666
傳 真 Fax	+ 886 2 8101 6667
網 址 Web	kpmg.com/tw

Independent Auditors' Review Report

To the Board of Directors Excelsior Medical Co., Ltd.:

Introduction

We have reviewed the accompanying consolidated balance sheets of Excelsior Medical Co., Ltd. and its subsidiaries as of June 30, 2026 and 2025, and the consolidated statements of comprehensive income for the three months and six months ended June 30, 2026 and 2025, as well as the changes in equity and cash flows for the six months ended June 30, 2026 and 2025, and notes to the consolidated financial statements, including a summary of significant accounting policies. Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and International Accounting Standard 34, "Interim Financial Reporting" endorsed and issued into effect by the Financial Supervisory Commission of the Republic of China. Our responsibility is to express a conclusion on the consolidated financial statements based on our reviews.

Scope of Review

Except as explained in the Basis for Qualified Conclusion paragraph, we conducted our reviews in accordance with the Standard on Review Engagements 2410, "Review of Financial Information Performed by the Independent Auditor of the Entity" of the Republic of China. A review of the consolidated financial statements consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing of the Republic of China and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Basis for Qualified Conclusion

As stated in Note (4)(b), the consolidated financial statements included the financial statements of certain non-significant subsidiaries, which were not reviewed by independent auditors. These financial statements reflect total assets amounting to \$1,902,497 thousand and \$684,324 thousand, constituting 8.99% and 3.71% of consolidated total assets as of June 30, 2026 and 2025, respectively, total liabilities amounting to \$1,080,298 thousand and \$93,260 thousand, constituting 13.59% and 1.22% of consolidated total liabilities as of June 30, 2026 and 2025, respectively, and total comprehensive (loss) income amounting to gains \$23,364 thousand, gains \$11,152 thousand, gains \$43,427 thousand and gains \$20,331 thousand, constituting 17.07%, 31.39%, 10.70% and 9.28% of consolidated total comprehensive (loss) income for the three months ended June 30, 2026 and 2025 and for the six months ended June 30, 2026 and 2025, respectively.

Furthermore, as stated in Note (6)(g), the other equity accounted investments of Excelsior Medical Co., Ltd. and its subsidiaries in its investee companies of \$3,116,976 thousand and \$4,076,220 thousand as of June 30, 2026 and 2025, respectively, and its share of comprehensive income of associates and joint ventures accounted for using equity method on these investee companies of gains \$136,241 thousand, gains \$137,806 thousand, gains \$239,185 thousand and gains \$231,774 thousand for the three months ended June 30, 2026 and 2025 and for the six months ended June 30, 2026 and 2025, respectively, were recognized solely on the financial statements prepared by these investee companies, but not reviewed by independent auditors.



Qualified Conclusion

Except for the adjustments, if any, as might have been determined to be necessary had the financial statements of certain consolidated subsidiaries and equity accounted investee companies described in the Basis for Qualified Conclusion paragraph above been reviewed by independent auditors, based on our reviews, nothing has come to our attention that causes us to believe that the accompanying consolidated financial statements do not present fairly, in all material respects, the consolidated financial position of Excelsior Medical Co., Ltd. and its subsidiaries as of June 30, 2026 and 2025, and of its consolidated financial performance for the three months and six months ended June 30, 2026 and 2025, as well as its consolidated cash flows for the six months ended June 30, 2026 and 2025 in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and International Accounting Standard 34, “Interim Financial Reporting” endorsed and issued into effect by the Financial Supervisory Commission of the Republic of China.

The engagement partners on the reviews resulting in this independent auditors’ review report are Kuo, Rou-Lan and Chen, Chun-Kuang.

KPMG

Taipei, Taiwan (Republic of China)
August 7, 2026

Notes to Readers

The accompanying consolidated financial statements are intended only to present the consolidated statement of financial position, financial performance and cash flows in accordance with the accounting principles and practices generally accepted in the Republic of China and not those of any other jurisdictions. The standards, procedures and practices to review such consolidated financial statements are those generally accepted and applied in the Republic of China.

The independent auditors’ review report and the accompanying consolidated financial statements are the English translation of the Chinese version prepared and used in the Republic of China. If there is any conflict between, or any difference in the interpretation of the English and Chinese language independent auditors’ review report and consolidated financial statements, the Chinese version shall prevail.

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

JUNE 30, 2026 AND 2025

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS)

		June 30, 2026		December 31, 2025		June 30, 2025						June 30, 2026		December 31, 2025		June 30, 2025	
ASSETS		Amount	%	Amount	%	Amount	%			LIABILITIES AND EQUITY		Amount	%	Amount	%	Amount	%
Current assets:										Current liabilities:							
1100	Cash and cash equivalents (Note (6)(a))	\$ 3,335,734	16	2,847,128	15	2,324,907	13	2100		Short-term borrowings (Note (6)(n))		\$ 641,550	3	1,343,221	7	822,216	4
1136	Current financial assets at amortized cost (Note (6)(d))	1,092,135	5	612,160	3	538,340	3	2120		Current financial liabilities at fair value through profit or loss		315	-	-	-	1,120	-
1151	Notes receivable (Notes (6)(e), (7) and (8))	176,552	1	188,111	1	203,464	1			(Note (6)(b))							
1152	Other notes receivable (Notes (6)(e), (7) and (8))	171,164	1	213,167	1	248,262	1	2130		Current contract liabilities		545,483	3	572,217	3	534,663	3
1170	Accounts receivable (Notes (6)(e) and (7))	2,049,745	10	1,769,796	10	1,777,347	10	2150		Notes payable		4,348	-	6,367	-	5,568	-
1200	Other receivables (Notes (6)(e) and (7))	3,026,124	14	3,036,901	16	3,503,539	19	2170		Accounts payable (Note (7))		1,018,540	5	1,139,987	6	1,052,716	6
130X	Inventories (Note (6)(f))	1,428,797	7	1,391,669	8	1,320,184	7	2200		Other payables (Notes (6)(o) and (7))		3,106,206	15	2,596,329	14	3,619,937	19
1476	Other current financial assets (Note (8))	100,463	-	75,185	-	67,005	-	2230		Current tax liabilities		130,207	1	108,869	-	104,844	-
1479	Other current assets, others	291,312	1	232,175	1	225,823	1	2280		Current lease liabilities (Notes (6)(q) and (7))		241,581	1	140,406	1	127,679	1
		11,672,026	55	10,366,292	55	10,208,871	55	2399		Other current liabilities, others (Notes (6)(p) and (7))		302,036	1	284,607	1	305,404	2
	Non-current assets:											5,990,266	29	6,192,003	32	6,574,147	35
1517	Non-current financial assets at fair value through other comprehensive income (Note (6)(c))	781,993	4	881,474	5	703,766	4			Non-Current liabilities:							
								2540		Long-term borrowings (Note (6)(n))		350,000	2	350,000	2	350,000	2
1550	Investments accounted for using equity method (Note (6)(g))	3,116,976	15	4,216,105	22	4,077,227	22	2570		Deferred tax liabilities (Note (6)(t))		356,307	2	369,847	2	341,756	2
1600	Property, plant and equipment (Notes (6)(j) and (8))	920,960	4	756,005	4	775,831	4	2580		Non-current lease liabilities (Notes (6)(q) and (7))		1,177,157	5	320,279	2	339,583	2
1755	Right-of-use assets (Note (6)(k))	988,672	5	272,114	1	283,443	2	2640		Net defined benefit liability (Note (6)(s))		5,622	-	5,020	-	4,143	-
1760	Investment property, net (Notes (6)(l) and (8))	1,592,090	7	1,598,242	8	1,604,394	9	2650		Credit balance of investments accounted for using equity method		-	-	-	-	1,007	-
1780	Intangible assets (Note (6)(m))	217,542	1	46,757	-	45,485	-			(Note (6)(g))							
1840	Deferred tax assets (Note (6)(t))	110,799	-	115,355	1	112,225	1	2670		Other non-current liabilities, others		72,309	-	15,441	-	15,016	-
1930	Long-term notes and accounts receivable (Note (6)(e))	1,227,986	6	333,936	2	324,885	2					1,961,395	9	1,060,587	6	1,051,505	6
1975	Net defined benefit asset (Note (6)(s))	60,048	-	62,527	-	51,516	-			Total liabilities		7,951,661	38	7,252,590	38	7,625,652	41
1980	Other non-current financial assets (Note (8))	322,340	2	316,480	2	220,411	1										
1990	Other non-current assets, others	144,449	1	11,910	-	21,229	-			Equity attributable to owners of parent (Note (6)(u)):							
		9,483,855	45	8,610,905	45	8,220,412	45	3100		Share capital		1,883,674	9	1,715,674	9	1,633,975	9
								3150		Stock dividend to be distributed		-	-	-	-	81,699	-
								3200		Capital surplus		4,248,985	20	3,390,833	18	3,382,788	19
								3300		Retained earnings		3,464,065	16	3,740,835	20	3,343,199	18
								3400		Other equity		216,767	1	344,945	2	44,372	-
										Total equity attributable to owners of parent		9,813,491	46	9,192,287	49	8,486,033	46
								36XX		Non-controlling interests (Notes (6)(i) and (u))		3,390,729	16	2,532,320	13	2,317,598	13
										Total equity		13,204,220	62	11,724,607	62	10,803,631	59
TOTAL ASSETS		\$ 21,155,881	100	18,977,197	100	18,429,283	100	TOTAL LIABILITIES AND EQUITY				\$ 21,155,881	100	18,977,197	100	18,429,283	100

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
FOR THE THREE MONTHS AND SIX MONTHS ENDED JUNE 30, 2026 AND 2025
(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, EXCEPT EARNINGS PER SHARE)

		For the Three Months ended June 30,				For the Six Months Ended June 30,			
		2026		2025		2026		2025	
		Amount	%	Amount	%	Amount	%	Amount	%
4000	Operating revenue (Notes (6)(x) and (7))	\$ 2,386,244	100	2,167,649	100	4,729,202	100	4,316,974	100
5000	Operating costs (Notes (6)(f) and (7))	1,868,638	78	1,700,124	78	3,712,310	79	3,393,676	79
	Gross profit from operations	517,606	22	467,525	22	1,016,892	21	923,298	21
5910	Less: Unrealized profit from sales	24,721	1	22,376	1	44,875	1	42,925	1
5920	Add: Realized profit from sales	24,574	1	21,431	-	41,969	1	43,794	1
		517,459	22	466,580	21	1,013,986	21	924,167	21
	Operating expenses:								
6100	Selling expenses (Note (7))	190,846	8	177,299	8	399,018	8	360,355	8
6200	Administrative expenses (Note (7))	130,589	6	91,917	4	234,690	5	188,756	4
6300	Research and development expenses	679	-	58	-	1,011	-	58	-
6450	Expected credit loss (gain) (Note (6)(e))	1,847	-	(2,961)	-	5,367	-	(6,465)	-
		323,961	14	266,313	12	640,086	13	542,704	12
		193,498	8	200,267	9	373,900	8	381,463	9
	Net operating income								
	Non-operating income and expenses:								
7100	Interest income (Note (6)(z))	21,602	1	18,041	-	39,960	1	41,364	1
7010	Other income (Notes (6)(z) and (7))	662	-	2,731	-	2,349	-	3,348	-
7020	Other gains and losses (Notes (6)(z) and (7))	75,294	3	(18,547)	-	73,892	1	(11,798)	-
7050	Finance costs (Notes (6)(z) and (7))	(9,326)	-	(8,175)	-	(17,379)	-	(16,757)	-
7060	Share of profit of associates and joint ventures accounted for using equity method(Note (6)(g))	136,241	5	137,806	6	239,185	5	231,774	5
		224,473	9	131,856	6	338,007	7	247,931	6
7900	Profit before tax	417,971	17	332,123	15	711,907	15	629,394	15
7950	Less: Tax expense (Note (6)(t))	72,411	3	58,999	3	129,841	3	116,029	3
	Profit	345,560	14	273,124	12	582,066	12	513,365	12
	Other comprehensive income (loss):								
8310	Items that may not be reclassified subsequently to profit or loss:								
8316	Unrealized gains (losses) from investments in equity instruments measured at fair value through other comprehensive income	(104,085)	(4)	76,710	3	(94,079)	(2)	48,190	1
8320	Share of other comprehensive income of associates and joint ventures accounted for using equity method, components of other comprehensive income that will not be reclassified to profit or loss	(76,635)	(3)	(34,506)	(2)	(98,221)	(2)	(23,354)	(1)
8349	Less: Income tax related to components of other comprehensive income that will not be reclassified to profit or loss	(22,086)	(1)	17,389	-	(18,239)	-	13,037	-
	Total items that will not be reclassified subsequently to profit and loss	(158,634)	(6)	24,815	1	(174,061)	(4)	11,799	-
8360	Items that will be reclassified to profit or loss								
8361	Exchange differences on translation	(52,605)	(2)	(390,764)	(18)	6,554	-	(344,434)	(8)
8370	Share of other comprehensive income of associates and joint ventures accounted for using equity method, components of other comprehensive income that will be reclassified to profit or loss	2,509	-	55,726	3	(8,714)	-	36,760	1
8399	Less: Income tax related to components of other comprehensive income that will be reclassified to profit or loss	(41)	-	(1,569)	-	126	-	(1,591)	-
	Total items that will be reclassified subsequently to profit and loss	(50,055)	(2)	(333,469)	(15)	(2,286)	-	(306,083)	(7)
	Other comprehensive income, net	(208,689)	(8)	(308,654)	(14)	(176,347)	(4)	(294,284)	(7)
8500	Total comprehensive income	\$ 136,871	6	(35,530)	(2)	405,719	8	219,081	5
	Profit attributable to:								
8610	Owners of parent	\$ 308,497	12	229,822	10	513,677	11	425,065	10
8620	Non-controlling interests	37,063	2	43,302	2	68,389	1	88,300	2
		\$ 345,560	14	273,124	12	582,066	12	513,365	12
	Comprehensive income attributable to:								
8710	Owners of parent	\$ 180,195	8	(81,927)	(4)	405,033	8	135,949	3
8720	Non-controlling interests	(43,324)	(2)	46,397	2	686	-	83,132	2
		\$ 136,871	6	(35,530)	(2)	405,719	8	219,081	5
	Earnings per share (Note (6)(w))								
9750	Basic earnings per share (NT dollars)	\$ 1.66		1.41		2.77		2.60	
9850	Diluted earnings per share (NT dollars)	\$ 1.66		1.40		2.75		2.59	

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY

FOR THE SIX MONTHS ENDED JUNE 30, 2026 AND 2025

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS)

	Equity attributable to owners of parent										
	Share capital			Retained earnings			Total other equity interest				
	Ordinary shares	Stock dividend to be distributed	Capital surplus	Legal reserve	Special reserve	Unappropriated retained earnings	Exchange differences on translation of foreign financial statements	Unrealized gains (losses) from financial assets measured at fair value through other comprehensive income	Equity attributable to owners of parent	Non-controlling interests	Total equity
Balance as of January 1, 2025	\$ 1,633,975	-	3,382,788	1,052,282	-	2,567,708	(10,729)	344,217	8,970,241	2,387,112	11,357,353
Profit for the year	-	-	-	-	-	425,065	-	-	425,065	88,300	513,365
Other comprehensive income (loss) for the year	-	-	-	-	-	-	(269,881)	(19,235)	(289,116)	(5,168)	(294,284)
Total comprehensive income (loss) for the year	-	-	-	-	-	425,065	(269,881)	(19,235)	135,949	83,132	219,081
Appropriation and distribution of retained earnings:											
Legal reserve appropriated	-	-	-	78,654	-	(78,654)	-	-	-	-	-
Cash dividends of ordinary share	-	-	-	-	-	(620,910)	-	-	(620,910)	-	(620,910)
Stock dividends of ordinary share	-	81,699	-	-	-	(81,699)	-	-	-	-	-
Changes in ownership interests in subsidiaries	-	-	-	-	-	753	-	-	753	-	753
Changes in non-controlling interests	-	-	-	-	-	-	-	-	-	(152,646)	(152,646)
Balance at June 30, 2025	\$ 1,633,975	81,699	3,382,788	1,130,936	-	2,212,263	(280,610)	324,982	8,486,033	2,317,598	10,803,631
Balance at January 1, 2026	\$ 1,715,674	-	3,390,833	1,130,936	-	2,609,899	(43,667)	388,612	9,192,287	2,532,320	11,724,607
Profit for the year	-	-	-	-	-	513,677	-	-	513,677	68,389	582,066
Other comprehensive income (loss) for the year	-	-	-	-	-	-	21,287	(129,931)	(108,644)	(67,703)	(176,347)
Total comprehensive income (loss) for the year	-	-	-	-	-	513,677	21,287	(129,931)	405,033	686	405,719
Appropriation and distribution of retained earnings:											
Legal reserve appropriated	-	-	-	82,345	-	(82,345)	-	-	-	-	-
Cash dividends of ordinary share	-	-	-	-	-	(809,980)	-	-	(809,980)	-	(809,980)
Changes in equity of associates and joint ventures accounted for using equity method	-	-	-	-	-	(1)	-	-	(1)	-	(1)
Capital increased by cash	168,000	-	840,000	-	-	-	-	-	1,008,000	-	1,008,000
Changes in ownership interests in subsidiaries	-	-	-	-	-	19,534	-	(19,534)	-	-	-
Share-based payments	-	-	18,152	-	-	-	-	-	18,152	2,912	21,064
Changes in non-controlling interests	-	-	-	-	-	-	-	-	-	854,811	854,811
Balance at June 30, 2026	\$ 1,883,674	-	4,248,985	1,213,281	-	2,250,784	(22,380)	239,147	9,813,491	3,390,729	13,204,220

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

FOR THE SIX MONTHS ENDED JUNE 30, 2026 AND 2025

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS)

	For the Six Months Ended June 30,	
	2026	2025
Cash flows from operating activities:		
Profit before tax	\$ 711,907	629,394
Adjustments:		
Adjustments to reconcile profit (loss):		
Depreciation expense	161,569	152,314
Amortization expense	4,328	3,601
Expected credit loss (gain)	5,367	(6,465)
Net gain on financial assets or liabilities at fair value through profit or loss	296	2,545
Interest expense	17,379	16,757
Interest income	(39,960)	(41,364)
Dividend income	(624)	(1,577)
Compensation cost from share-based payments	21,064	-
Share of profit of associates and joint ventures accounted for using equity method	(239,185)	(231,774)
Gain on disposal of property, plant and equipment	(54)	(406)
Gain on disposal of investments	(71,120)	-
Unrealized profit from sales	44,875	42,925
Realized profit from sales	(41,969)	(43,794)
Profit from lease modification	(141)	(97)
Total adjustments to reconcile profit	<u>(138,175)</u>	<u>(107,335)</u>
Changes in operating assets and liabilities:		
Changes in operating assets:		
Notes receivable	13,386	16,500
Accounts receivable	(55,581)	(59,454)
Other receivables and notes	53,325	(99,816)
Inventories	(45,509)	26,427
Net defined benefit asset	2,479	2,435
Other current assets	<u>(3,904)</u>	<u>(65,715)</u>
Total changes in operating assets	<u>(35,804)</u>	<u>(179,623)</u>
Changes in operating liabilities:		
Contract liabilities	(26,734)	(8,932)
Notes payable	(2,717)	3,637
Accounts payable	(133,240)	75,677
Other payables	289,441	(1,687,774)
Other current liabilities	(2,931)	(6,329)
Net defined benefit liability	602	(225)
Other operating liabilities	<u>(44,634)</u>	<u>411</u>
Total changes in operating liabilities	<u>79,787</u>	<u>(1,623,535)</u>
Total changes in operating assets and liabilities	<u>43,983</u>	<u>(1,803,158)</u>
Total adjustments	<u>(94,192)</u>	<u>(1,910,493)</u>
Cash inflow (outflow) generated from operations	617,715	(1,281,099)
Interest received	41,279	41,931
Income taxes paid	<u>(113,384)</u>	<u>(111,476)</u>
Net cash flows from (used in) operating activities	<u>545,610</u>	<u>(1,350,644)</u>

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE SIX MONTHS ENDED JUNE 30, 2026 AND 2025
(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS)

	For the Six Months Ended June 30,	
	2026	2025
Cash flows (used in) from investing activities:		
Acquisition of financial assets at fair value through other comprehensive income	(79,463)	-
Proceeds from disposal of financial assets at fair value through other comprehensive income	84,705	-
Acquisition of financial assets at amortized cost	(169,027)	(343,807)
Proceeds from disposal of financial assets at amortized cost	153,027	526,925
Acquisition of financial assets at fair value through profit or loss	-	(2,124)
Proceeds from disposal of financial assets at fair value through profit or loss	19	816
Net cash flow from acquisition of subsidiaries	572,788	-
Acquisition of property, plant and equipment	(64,857)	(46,089)
Proceeds from disposal of property, plant and equipment	54	406
Increase in refundable deposits	(5,912)	(12,376)
Acquisition of intangible assets	(1,083)	(1,688)
Other financial assets	7,628	33,907
Other non-current assets	729	(7,137)
Dividends received	192,312	12,130
Net cash flows from investing activities	690,920	160,963
Cash flows from (used in) financing activities:		
Decrease in short-term borrowings	(701,671)	(95,315)
Proceeds from long-term borrowings	-	350,000
Increase (decrease) in guarantee deposits received	44,873	(26)
Payment of lease liabilities	(87,202)	(67,527)
Cash dividends paid	(808,711)	(620,910)
Capital increased by cash	1,008,000	-
Interest paid	(19,840)	(14,377)
Change in non-controlling interests	(157,274)	(152,646)
Net cash flows used in financing activities	(721,825)	(600,801)
Effect of exchange rate changes on cash and cash equivalents	(26,099)	(73,815)
Net increase (decrease) in cash and cash equivalents	488,606	(1,864,297)
Cash and cash equivalents at beginning of period	2,847,128	4,189,204
Cash and cash equivalents at end of period	\$ 3,335,734	2,324,907

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2026 AND 2025

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

(1) Company History

Excelsior Medical Co., Ltd. (the Company) was incorporated on March 15, 1988 as a company limited by shares and registered under the Ministry of Economic Affairs, R.O.C. The address of the Company's registered office is 17F., No.880, Zhongzheng Rd., Zhonghe Dist., New Taipei City 235, Taiwan, R.O.C.. The Company and its subsidiaries (the Group) engaged primarily in the sale of medical supplies and equipment, medicines and home medical devices.

The Company's shares were traded on the Taipei Exchange (formerly the GreTai Securities Market) from June 8, 2001 to December 31, 2007 and have been traded on the Taiwan Stock Exchange since December 31, 2007.

(2) Financial Statements Authorization Date and Authorization Process

The consolidated financial statements were authorized for issuance by the Board of Directors on August 7, 2026.

(3) New Standards, Amendments and Interpretations Adopted:

- (a) The impact of the IFRS Accounting Standards endorsed by the Financial Supervisory Commission, R.O.C. which have already been adopted.

The Group has initially adopted the following new amendments, which do not have a significant impact on its consolidated financial statements, from January 1, 2026:

- IFRS 17 “Insurance Contracts” and amendments to IFRS 17 “Insurance Contracts”
- Amendments to IFRS 9 and IFRS 7 “Amendments to the Classification and Measurement of Financial Instruments”
- Annual Improvements to IFRS Accounting Standards—Volume 11
- Amendments to IFRS 9 and IFRS 7 “Contracts Referencing Nature-dependent Electricity”

- (b) The impact of IFRS Accounting Standards endorsed by the FSC but not yet effective

The Group assesses that the adoption of the following new amendments, effective for annual period beginning on January 1, 2027, would not have a significant impact on its consolidated financial statements:

- IFRS 19 “Subsidiaries without Public Accountability: Disclosures” and amendments to IFRS 19
- Amendments to IAS 21 “Translation to a Hyperinflationary Presentation Currency”

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2026 AND 2025

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

The Group expects to adopt the following new and amended standards, which effective for annual period beginning on January 1, 2028:

(i) IFRS 18 “Presentation and Disclosure in Financial Statements”

The new standard introduces three categories of income and expenses, two income statement subtotals and one single note on management performance measures. The three amendments, combined with enhanced guidance on how to disaggregate information, set the stage for better and more consistent information for users, and will affect all the entities.

- A more structured income statement: under current standards, companies use different formats to present their results, making it difficult for investors to compare financial performance across companies. The new standard promotes a more structured income statement, introducing a newly defined ‘operating profit’ subtotal and a requirement for all income and expenses to be allocated between three new distinct categories based on a company’s main business activities.
- Management performance measures (MPMs): the new standard introduces a definition for management performance measures, and requires companies to explain in a single note to the financial statements why the measure provides useful information, how it is calculated and reconcile it to an amount determined under IFRS Accounting Standards.
- Greater disaggregation of information: the new standard includes enhanced guidance on how companies group information in the financial statements. This includes guidance on whether information is included in the primary financial statements or is further disaggregated in the notes.

The new standard introduces consequential amendments to IAS 7, which require to use the newly defined operating profit subtotal as the starting point for the statement of cash flows when presenting operating cash flows under the indirect method. The consequential amendments also provide specific guidance on the classification of interest and dividend cash flows.

The Group is evaluating the impact on its consolidated financial statements upon the initial adoption of the new standard.

(ii) Amendments to IAS 28 “The Fair Value Option for Investments in Associates and Joint Ventures”

The Group does not expect the amendments to have a significant impact on its consolidated financial statements.

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2026 AND 2025

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

- (c) The impact of IFRS Accounting Standards issued by IASB but not yet endorsed by the FSC

The Group does not expect the following new and amended standards, which have yet to be endorsed by the FSC, to have a significant impact on its consolidated financial statements:

- Amendments to IFRS 10 and IAS 28 “Sale or Contribution of Assets Between an Investor and Its Associate or Joint Venture”
- IFRS 20 “Regulatory Assets and Regulatory Liabilities”

(4) Summary of material accounting policies

(a) Statement of compliance

These consolidated financial statements have been prepared in accordance with the preparation and guidelines of IAS 34 “Interim Financial Reporting” which are endorsed and issued into effect by FSC, and do not include all of the information required by the Regulations and International Financial Reporting Standards, International Accounting Standards, IFRIC Interpretations and SIC Interpretations endorsed and issued into effect by the FSC (hereinafter referred to IFRS Accounting Standards endorsed by the FSC) for a complete set of the annual consolidated financial statements.

Except the following accounting policies mentioned below, the material accounting policies adopted in the consolidated financial statements are the same as those in the consolidated financial statement for the year ended December 31, 2025. For the related information, please refer to note 4 of the consolidated financial statements for the year ended December 31, 2025.

(b) Basis of consolidation

1. List of subsidiaries in the consolidated financial statements :

Name of Investor	Name of Subsidiary	Principal Activity	Shareholding			Note
			June 30, 2026	December 31, 2025	June 30, 2025	
The Company	Dynamic Medical Technologies Inc. (“Dynamic”)	Sale, maintenance and lease of laser medical equipment for beauty treatment, and sale of consumables of beauty treatment and cosmetic products	33.97 %	33.97 %	33.96 %	Note 1、2
”	Asia Best Life Care Co., Ltd. (“Asia Best Life Care”)	Long-term care and rehabilitation services, leasing business, sale of medical consumables and information services.	49.02 %	49.02 %	49.38 %	Note 3
”	Excelsior Healthcare Co., Limited (Excelsior Healthcare)	Investment business	100.00 %	100.00 %	100.00 %	
”	Arich Enterprise Co., Ltd. (Arich)	Sale of medicines, and logistics service	40.00 %	40.00 %	40.00 %	Note 1
”	Excelsior Asset Management Co., Ltd. (“Excelsior Asset”)	Sales of medical equipment, precision instrument and real estate	100.00 %	100.00 %	100.00 %	
The Company and Excelsior Healthcare	Excelsior Medical (HK) Co., Limited (“Hong Kong Excelsior”)	Investment business	100.00 %	100.00 %	100.00 %	
Dynamic	Dynamic Medical Technologies (Hong Kong) Ltd. (“Hong Kong Dynamic”)	Sale of cosmetic health care products	100.00 %	100.00 %	100.00 %	

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2026 AND 2025

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

Name of Investor	Name of Subsidiary	Principal Activity	Shareholding			Note
			June 30, 2026	December 31, 2025	June 30, 2025	
Dynamic	CYJ International Taiwan Inc. (CYJ Taiwan)	Sales of lifestyle beauty products and treatments, and sales of medical beauty products.	55.41 %	55.41 %	55.41 %	
The Company and Dynamic	Excelsior Beauty Co., Ltd. ("Excelsior Beauty")	Sales of lifestyle beauty products and treatments, and sales of medical beauty products.	94.91 %	94.91 %	94.91 %	
Hong Kong Dynamic	Guangzhou Dynamic Inc. ("Guangzhou Dynamic")	Sale and maintenance of medical equipment	100.00 %	100.00 %	100.00 %	Note 4
Arich Enterprise Co., Ltd.	Arich Best Chain Co., Ltd. (Arich Best Chain)	Logistics business	100.00 %	100.00 %	100.00 %	"
Excelsior Healthcare	EG Healthcare, Inc.	Sale and lease of medical equipment, and medical management consultancy service	99.99 %	99.99 %	99.99 %	"
"	Excelsior Investment (Malaysia) Co., Ltd.	Investment business	100.00 %	100.00 %	100.00 %	"
Hong Kong Excelsior	SinoExcelsior Investment Inc. ("SinoExcelsior Investment")	Sale of medical equipment, and medical management consultancy service	100.00 %	100.00 %	100.00 %	"
Excelsior Investment (Malaysia) Co., Ltd.	Renal Laboratories Sdn. Bhd.	Manufacture of medical equipment	81.90 %	81.90 %	81.90 %	"
"	Medi-Chem Systems Sdn. Bhd.	Sale of medical equipment	70.00 %	70.00 %	70.00 %	"
Medi-Chem Systems Sdn. Bhd.	Renal Management Sdn. Bhd.	Lease business	100.00 %	100.00 %	100.00 %	"
Asia Best Life Care Co., Ltd.	Excelsior Long Term Care Corporation Entity ("Excelsior Long Term Care")	Long-term care and rehabilitation services	99.00 %	99.00 %	99.00 %	Note 3 - 4
"	Excelsior N Long Term Care Corporation (Excelsior N Long Term Care")	Long-term care and rehabilitation services	99.00 %	99.00 %	99.00 %	"
"	Anxin Nice Care Co., Ltd. ("Anxin Nice Care")	Home-based care services	100.00 %	100.00 %	100.00 %	"
Anxin Nice Care Co., Ltd.	Fengxuan International Business Co., Ltd. ("Fengxuan")	Home-based care services	100.00 %	100.00 %	100.00 %	"
"	LiJi Long Term Care Intergration Technology Co., Ltd. ("Ligi")	Home-based care services	100.00 %	100.00 %	- %	"
"	Shi Wang Life Co., Ltd. ("Shi Wang")	Home-based care services	100.00 %	100.00 %	- %	"

Note 1: Although the Company holds less than 50% of the shares of Dynamic and Arich, these companies' other equity shares are highly separated. Therefore, the Company still maintains control over Dynamic and Arich, and these companies are included in the consolidated financial statements.

Note 2: The Company bought the fractional shares of Dynamic in September 2025 acquiring 0.004%, of Dynamic's shares, while still maintaining control over Dynamic.

Note 3: Asia Best Life care Co., Ltd. held a re-election of its Board of Directors on May 29, 2026. Following the re-election, the Group obtained a majority of the seats on the board and obtained control over Asia Best Life Care Co., Ltd. and its subsidiaries.

Note 4: Non-significant subsidiaries, which were not reviewed by independent auditors.

2.Subsidiaries excluded from the consolidated financial statements: None.

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2026 AND 2025

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

(c) Classification of Current and Non-Current Assets and Liabilities

The Group classifies the asset as current under one of the following criteria, and all other assets are classified as non-current.

- 1.It is expected to be realized, or intended to be sold or consumed, in the normal operating cycle;
- 2.It is held primarily for the purpose of trading;
- 3.It is expected to be realized within twelve months after the reporting period; or
- 4.The asset is cash or a cash equivalent (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period.

The Group classifies the liability as current under one of the following criteria, and all other liabilities are classified as non-current.

- 1.It is expected to be settled in the normal operating cycle;
- 2.It is held primarily for the purpose of trading;
- 3.It is due to be settled within twelve months after the reporting period; or
- 4.The Group does not have the right at the end of the reporting period to defer settlement of the liability for at least twelve months after the reporting period.

(d) Income Taxes

The income tax expenses have been prepared and disclosed in accordance with paragraph B12 of International Financial Reporting Standards 34, Interim Reporting.

Income tax expenses for the period are measured by multiplying together pre-tax income for the interim reporting period and the managements best estimate period annual tax rate.

Temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and their respective tax bases shall be measured based on the tax rates that have been enacted or substantively enacted at the time of the asset or liability is recovered or settled, and be recognized directly in equity or other comprehensive income as tax expense.

(e) Employee Benefits

The pension cost in the interim period was calculated and disclosed on a year-to-date basis by using the actuarially determined pension cost rate at the end of the prior fiscal year, adjusted for significant market fluctuations since that time and for significant curtailments, settlements, or other significant one-off events.

(f) Share-based Payment

The grant-date fair value of equity-settled share-based payment arrangements granted to employees is generally recognized as an expense, with a corresponding increase in equity, over the vesting period of the awards. The amount recognized as an expense is adjusted to reflect the number of awards for which the related service and non-market performance conditions are expected to be met, such that the amount ultimately recognized is based on the number of awards that meet the related service and non-market performance conditions at the vesting date.

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2026 AND 2025

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

For share-based payment awards with non-vesting conditions, the grant-date fair value of the share-based payment is measured to reflect such conditions, and there is no true-up for differences between expected and actual outcomes.

Grant date of a share-based payment award is the date which the Board of Directors and the employees have made an agreement on the price and number of the new award.

(g) Business Combination

The Company accounts for business combinations using the acquisition method. The goodwill arising from an acquisition is measured as the excess of (i) the consideration transferred (which is generally measured at fair value) and (ii) the amount of non-controlling interest in the acquiree, both over the identifiable net assets acquired at the acquisition date. If the amount calculated above is a deficit balance, the Company recognized that amount as a gain on a bargain purchase in profit or loss immediately after reassessing whether it has correctly identified all of the assets acquired and all of the liabilities assumed.

All acquisition-related transaction costs are expensed as incurred, except for the issuance of debt or equity instruments.

For each business combination, the Group measures any non-controlling interests in the acquiree either at fair value or at the non-controlling interest's proportionate share of the acquiree's identifiable net assets, if the non-controlling interests are present ownership interests and entitle their holders to a proportionate share of the acquiree's net assets in the event of liquidation. Other components of non-controlling interests are measured at their acquisition-date fair values, unless another measurement basis is required by the IFRSs endorsed by the FSC.

If the initial accounting for a business combination is incomplete by the end of the reporting period in which the combination occurs, provisional amounts for the items for which the accounting is incomplete are reported in the Group's financial statements. During the measurement period, the provisional amounts recognized at the acquisition date are retrospectively adjusted, or additional assets or liabilities are recognized to reflect new information obtained about facts and circumstances that existed as of the acquisition date. The measurement period will not exceed one year from the acquisition date.

(5) Significant Accounting Assumptions and Judgments, and Major Sources of Estimation Uncertainty

The preparation of the consolidated financial statements in conformity with the Regulations and IFRS Accounting Standards (in accordance with IAS 34 "Interim Financial Reporting" and endorsed by the FSC) requires management to make judgments, estimates and assumptions that affect the application of the accounting policies and the reported amount of assets, liabilities, income and expenses. Actual results may differ from these estimates.

The preparation of the consolidated interim financial statements, estimates and underlying assumptions are reviewed on an ongoing basis which are in conformity with the consolidated financial statements for the year ended December 31, 2025. For related information, please refer to note (5) of the consolidated financial statements for the year ended December 31, 2025.

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2026 AND 2025

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

(6) Explanation of Significant Accounts

Except for the following disclosures, there were no material differences in the disclosures of significant accounts between the interim consolidated financial statements for the current period and the 2025 consolidated financial statements. Please refer to Note (6) to the 2025 annual consolidated financial statements.

(a) Cash and cash equivalents

	June 30, 2026	December 31, 2025	June 30, 2025
Cash on hand, demand deposits and checking accounts	\$ 2,733,558	2,180,593	1,747,098
Time deposits	602,176	666,535	577,809
Cash and cash equivalents in consolidated statement of cash flows	<u>\$ 3,335,734</u>	<u>2,847,128</u>	<u>2,324,907</u>

The Group interest risk and sensibility analysis of the financial assets and liabilities was disclosed in Note (6)(aa).

(b) Financial assets or financial liabilities at fair value through profit or loss

	June 30, 2026	December 31, 2025	June 30, 2025
Held-for-trading financial liabilities			
Forward foreign exchange contracts	\$ <u>315</u>	<u>-</u>	<u>1,120</u>

The Group holds derivative financial instruments to hedge certain foreign exchange and interest rate risk exposures arising from its operating, financing and investing activities. The following derivative instruments, without the application of hedge accounting, were classified as mandatorily measured at fair value through profit or loss and held-for-trading financial liabilities:

Forward foreign exchange contracts:

June 30, 2026			
	Amount (in thousands)	Currency	Maturity period
Forward foreign exchange contracts purchased	JPY 65,315	JPY to TWD	2026.07
Forward foreign exchange contracts purchased	JPY 76,202	JPY to TWD	2026.08
June 30, 2025			
	Amount (in thousands)	Currency	Maturity period
Forward foreign exchange contracts purchased	JPY 137,395	JPY to TWD	2025.07~2025.08
Forward foreign exchange contracts purchased	USD 641	USD to TWD	2025.07

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2026 AND 2025

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

(c) Financial assets at fair value through other comprehensive income

	June 30, 2026	December 31, 2025	June 30, 2025
Equity investments at fair value through other comprehensive income			
Domestic listed shares	\$ 38,105	2,659	2,748
Foreign listed shares	166,473	248,855	141,448
Domestic unlisted shares	173,844	132,312	133,622
Foreign unlisted shares	403,571	497,648	425,948
Total	<u>\$ 781,993</u>	<u>881,474</u>	<u>703,766</u>

1. Equity investments at fair value through other comprehensive income

The Group designated the investments shown above as equity securities at fair value through other comprehensive income because these equity securities represent those investments that the Group intends to hold for long term for strategic purposes.

The Group has sold its common stocks designated at fair value through other comprehensive income because of operation strategies for the six months ended June 30, 2026. The shares sold had a fair value of \$84,705 thousand. The Group realized a gain of \$57,512 thousand, which was included in other comprehensive income (equity attributable to owners of parent), and thereafter, was transferred to retained earnings from other equity.

There were no disposals of strategic investments and transfers of any cumulative gain or loss within equity relating to these investments for the six months ended June 30, 2025.

2. For credit risk and market risk, please refer to Note (6)(aa).

3. The aforesaid financial assets were not pledged as collateral.

(d) Financial assets measured at amortized cost

	June 30, 2026	December 31, 2025	June 30, 2025
Time deposits with original maturity of more than 3 months	<u>\$ 1,092,135</u>	<u>612,160</u>	<u>538,340</u>

The Group has assessed that these financial assets are held to maturity to collect contractual cash flows, which consist solely of payments of principal and interest on principal amount outstanding. Therefore, these investments have been classified as financial assets measured at amortized cost.

The market interest rates of the time deposits with original maturity of more than 3 months were 0.95%~1.70%, 1.10%~1.70% and 1.10%~4.17% as of June 30, 2026, December 31, 2025 and June 30, 2025, respectively.

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2026 AND 2025

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

(e) Notes receivable, accounts receivable, lease payment receivable and other receivables

	June 30, 2026	December 31, 2025	June 30, 2025
Notes receivable	\$ 177,010	191,341	205,206
Other notes receivable	171,164	213,167	248,262
Accounts receivable	1,902,205	1,715,019	1,762,299
Receivable installments	279	809	1,567
Receivable installments - OCI	2,496	3,286	3,579
Lease payment receivable	1,436,466	440,703	389,925
Other receivables	3,029,099	3,039,008	3,505,485
Less: Loss allowance	(61,408)	(55,766)	(53,539)
Allowance for sales returns	(5,644)	(5,543)	(5,122)
Unrealized interests income	(96)	(113)	(165)
	<u><u>\$ 6,651,571</u></u>	<u><u>5,541,911</u></u>	<u><u>6,057,497</u></u>

The Group has assessed a portion of its trade receivables that was held within a business model whose objective is achieved by both collecting contractual cash flows and selling financial assets; therefore, such trade receivables were measured at fair value through other comprehensive income.

Arich Enterprise Co., Ltd. ("Arich") engages in medical logistics services, providing inventory management services, logistics services, customer service and domestic transportation planning services. Arich recognizes the medical logistics service revenue at a percentage of the net profit on its sale of medicines. The inventories for medical logistics services do not belong to Arich. The receivables from customers and the payables to medical companies are classified as other notes receivable, other trade receivables, other notes payable, and other trade payables.

The Group applies the simplified approach to provide for its expected credit losses, i.e. the use of lifetime expected loss provision for all receivables. To measure the expected credit losses, trade receivables have been grouped based on shared credit risk characteristics and the days past due, as well as incorporated forward looking information, including macroeconomic and relevant industry information. The loss allowance provision were determined as follows:

	June 30, 2026		
	Gross carrying amount	Weighted- average loss rate	Loss allowance provision
Current	\$ 6,551,027	0.35%	(23,000)
1 to 90 days past due	119,712	6.33%	(7,577)
91 to 180 days past due	15,397	29.01%	(4,466)
181 to 365 days past due	7,860	29.31%	(2,304)
More than 365 days past due	24,627	97.70%	(24,061)
	<u><u>\$ 6,718,623</u></u>		<u><u>(61,408)</u></u>

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2026 AND 2025

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

	December 31, 2025		
	Gross carrying amount	Weighted-average loss rate	Loss allowance provision
Current	\$ 5,506,809	0.35%	(19,130)
1 to 90 days past due	64,103	13.35%	(8,557)
91 to 180 days past due	4,730	28.33%	(1,340)
181 to 365 days past due	1,639	49.05%	(804)
More than 365 days past due	25,939	99.98%	(25,935)
	<u>\$ 5,603,220</u>		<u>(55,766)</u>
	June 30, 2025		
	Gross carrying amount	Weighted-average loss rate	Loss allowance provision
Current	\$ 5,976,144	0.23%	(13,975)
1 to 90 days past due	96,514	3.96%	(3,821)
91 to 180 days past due	7,921	21.30%	(1,687)
181 to 365 days past due	3,115	54.38%	(1,694)
More than 365 days past due	32,464	99.69%	(32,362)
	<u>\$ 6,116,158</u>		<u>(53,539)</u>

The Group's lease payment receivables were as follows:

	June 30, 2026	December 31, 2025	June 30, 2025
Less than 1 year	\$ 285,603	124,683	71,884
1 to 2 years	289,422	122,027	96,023
2 to 3 years	211,972	91,709	87,824
3 to 4 years	176,474	63,960	71,615
4 to 5 years	139,480	36,857	46,036
More than 5 years	1,354,565	59,201	73,286
	2,457,516	498,437	446,668
	(1,021,050)	(57,734)	(56,743)
	<u>\$ 1,436,466</u>	<u>440,703</u>	<u>389,925</u>

The Group entered into finance lease arrangements for certain vehicles and equipment. All leases were denominated in New Taiwan dollars. The term of finance leases entered into was 1 to 10 years.

The lease payment receivables as of June 30, 2026, December 31, 2025 and June 30, 2025 were neither past due nor impaired.

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2026 AND 2025

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

The movement in the allowance for notes and trade receivable was as follows:

	For the Six Months Ended June 30,	
	2026	2025
Balance as of January 1	\$ 55,766	64,032
Arising from the acquisition	651	-
Impairment losses recognized (reversed)	5,367	(6,465)
Amounts written off	-	(2,577)
Effect of movements in exchange rate	(376)	(1,451)
Balance as of June 30	<u><u>\$ 61,408</u></u>	<u><u>53,539</u></u>

As of June 30, 2026, December 31, 2025 and June 30, 2025, the receivables from installment sales were \$2,775 thousand, \$4,095 thousand and \$5,146 thousand, respectively, and the related unrealized interest income were \$96 thousand, \$113 thousand and \$165 thousand, respectively.

(f) Inventories

	June 30, 2026	December 31, 2025	June 30, 2025
Merchandise	\$ 1,355,416	1,359,048	1,274,008
Inventory in-transit	73,381	32,621	46,176
Total	<u><u>\$ 1,428,797</u></u>	<u><u>1,391,669</u></u>	<u><u>1,320,184</u></u>

The details of cost of goods sold were as follows :

	For the Three Months Ended June 30,		For the Six Months Ended June 30,	
	2026	2025	2026	2025
Cost of goods sold	\$ 1,608,632	1,475,560	3,235,403	2,958,732
Care service costs	29,032	-	29,032	-
(Reversal) losses on inventory valuation and obsolescence	(7,355)	(4,697)	(12,344)	(2,622)
Service Cost	71,708	74,001	150,141	142,738
Repair and maintenance costs	35,742	36,696	69,789	71,734
Others operating costs	130,879	118,564	240,289	223,094
Total	<u><u>\$ 1,868,638</u></u>	<u><u>1,700,124</u></u>	<u><u>3,712,310</u></u>	<u><u>3,393,676</u></u>

The factor leading to the net realizable value of inventories lower than the cost no longer exists, resulting in the net realizable value and the recognition of a gain on inventory recoveries for the three months ended June 30, 2026 and 2025 and for the six months ended June 30, 2026 and 2025.

As of June 30, 2026, December 31, 2025 and June 30, 2025, none of the combined company's inventories had been provided with pledge guarantees.

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2026 AND 2025

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

(g) Investments accounted for using equity method

A summary of the Group's financial information for investments accounted for using the equity method at the reporting date is as follows:

	June 30, 2026	December 31, 2025	June 30, 2025
Associates	<u>\$ 3,116,976</u>	<u>4,216,105</u>	<u>4,076,220</u>

1. Associates

Associates which are material to the Group consisted of the followings:

Name of Associates	Nature of Relationship with the Group	Main operating location/ Registered Country of the Company	Proportion of shareholding and voting rights		
			June 30, 2026	December 31, 2025	June 30, 2025
Asia Best Healthcare	Healthcare management services	Cayman Islands	48.47 %	48.47 %	48.47 %
Asia Best Life Care Co., Ltd.	Long-term care and rehabilitation services, leasing business, sale of medical consumables and information services	Taiwan	Note	49.02 %	49.38 %

Note: The Company obtained control over the company on May 29, 2026, by obtaining a majority of the seats on its Board of Directors. Accordingly, the company has been included in the Group's consolidated financial statement from that date.

1) Asia Best Healthcare:

	June 30, 2026	December 31, 2025	June 30, 2025
Current assets	\$ 1,149,735	1,026,727	917,624
Non-current assets	1,841,891	1,830,642	2,075,816
Current liabilities	(272,557)	(136,780)	(201,665)
Non-Current liabilities	(1,402,774)	(1,417,287)	(1,558,372)
Net assets	<u>\$ 1,316,295</u>	<u>1,303,302</u>	<u>1,233,403</u>
Net assets attributable to the Group	<u>\$ 645,812</u>	<u>618,784</u>	<u>584,358</u>
	For the Three Months Ended June 30,		For the Six Months Ended June 30,
	2026	2025	2026
Operating revenue	<u>\$ 62,655</u>	<u>21,393</u>	<u>104,644</u>
Profit	\$ 31,846	22,102	44,184
Other comprehensive income (loss)	2,276	88,981	(6,336)
Total comprehensive income	<u>\$ 34,122</u>	<u>111,083</u>	<u>37,848</u>
Comprehensive income attributable to the Group	<u>\$ 16,538</u>	<u>53,841</u>	<u>18,344</u>
	<u>58,804</u>		

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2026 AND 2025

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

2) Asia Best Life Care Co., Ltd.:

			December 31, 2025	June 30, 2025
Current assets			\$ 780,931	722,154
Non-current assets			1,650,824	1,700,662
Current liabilities			(117,647)	(190,751)
Non-Current liabilities			(317,861)	(340,784)
Net assets			<u>\$ 1,996,247</u>	<u>1,891,281</u>
Net assets attributable to the Group			<u>\$ 1,035,423</u>	<u>1,016,034</u>

The Group's financial information for investments accounted for using equity method that are individually insignificant was as follows:

		June 30, 2026	December 31, 2025	June 30, 2025
Carrying amount of individually insignificant associates' equity		\$ 2,471,164	2,561,898	2,475,828
	For the Three Months Ended June 30,	For the Three Months Ended June 30,	For the Six Months Ended June 30,	For the Six Months Ended June 30,
	2026	2025	2026	2025
Attributable to the Group				
Profit	\$ 112,593	111,533	190,787	174,440
Other comprehensive income	(75,228)	(21,909)	(103,215)	(20,798)
Total comprehensive income	\$ 37,365	89,624	87,572	153,642

None of the Group's investments using the equity method is provided as a pledge.

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2026 AND 2025

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

2.The unreviewed financial statements of investments accounted for using equity method

Investments were accounted for by using the equity method, and the share of profit or loss and other comprehensive income of those investments were calculated based on the financial statements that have not been reviewed.

(h) Aquisition of subsidiary

1.Acquisition of subsidiary- Asia Best Life Care Co., Ltd.

On May 29, 2026, the Group obtained control over Asia Best Life Care Co., Ltd. ("Asia Best Life Care ") through the re-election of its Board of Directors.

The main categories of consideration transferred, the assets acquired and liabilities assumed on the acquisition date, and the amount of goodwill recognized are summarized as follows:

1) Acquisition of identifiable assets and assumption of liabilities

The fair value of the identifiable assets acquired and liabilities assumed at the acquisition date was as follows:

Cash and cash equivalents	\$	572,788
Current financial assets at amortized cost		463,000
Accounts receivable		165,062
Other receivables		2,289
Other current assets		53,627
Inventories		5,194
Right-of-use assets		657,971
Property, plant and equipment		189,996
Intangible assets		12,721
Long-term notes receivable		929,900
Deferred tax assets		820
Other non-current financial assets		32,854
Other non-current assets		134,183
Notes payable		(698)
Accounts payable		(11,793)
Current tax liabilities		(14,831)
Other payables		(219,582)
Other current liabilities		(20,360)
Other non-current liabilities		(56,629)
Lease liabilities		(911,252)
Fair value of identifiable net assets	\$	<u><u>1,985,260</u></u>

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2026 AND 2025

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

2) Goodwill

Goodwill arising from the acquisition has been recognized as follows:

Add: Fair value of the previously held equity interest in the acquiree	\$ 1,149,311
Add: Non-controlling interests	1,012,085
Less: Fair value of net identifiable assets	<u>(1,985,260)</u>
Goodwill	<u><u>\$ 176,136</u></u>

The consolidated company recognized a gain of NT\$71,120 thousand resulting from the remeasurement of the fair value of its 49.02% equity interest in Asia Best Life Care Co., Ltd. ,which was held prior to the acquisition date. This gain was recognized under “Other gains and losses” in the consolidated statement of comprehensive income. Please refer to Note 6(z), Non-operating Income and Expenses.

(i) Material non-controlling interests of subsidiaries

The material non-controlling interests of subsidiaries were as follows:

Subsidiaries	Main operating location/ Registered Country of the Company	Proportion of shareholding and voting rights		
		June 30, 2026	December 31, 2025	June 30, 2025
Dynamic	Taiwan	66.03 %	66.03 %	66.04 %
Arich	Taiwan	60.00 %	60.00 %	60.00 %
Asia Best Life Care	Taiwan	50.98 %	- %	- %

The summarized financial information below represents amounts before intragroup eliminations were as follows:

1. Collective financial information of Dynamic and its subsidiaries:

	June 30, 2026	December 31, 2025	June 30, 2025
Current assets	\$ 1,847,081	1,878,616	1,770,830
Non-current assets	1,114,253	1,248,031	1,088,331
Current liabilities	(851,035)	(869,772)	(826,469)
Non-Current liabilities	<u>(323,117)</u>	<u>(364,589)</u>	<u>(352,184)</u>
Net assets	<u><u>\$ 1,787,182</u></u>	<u><u>1,892,286</u></u>	<u><u>1,680,508</u></u>
Non-controlling interests	<u><u>\$ 1,105,786</u></u>	<u><u>1,239,231</u></u>	<u><u>914,041</u></u>

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2026 AND 2025

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

	For the Three Months Ended June 30,		For the Six Months Ended June 30,	
	2026	2025	2026	2025
Operating revenue	\$ <u>344,397</u>	<u>327,219</u>	<u>687,173</u>	<u>678,454</u>
Net income	\$ 46,862	43,893	82,081	90,791
Other comprehensive income (loss)	(39,110)	18,424	1,863	8,262
Total comprehensive income	\$ <u>7,752</u>	<u>62,317</u>	<u>83,944</u>	<u>99,053</u>
Profit, attributable to non-controlling interests	\$ <u>28,186</u>	<u>26,587</u>	<u>47,830</u>	<u>54,979</u>
Comprehensive income, attributable to non-controlling interests	\$ <u>59,702</u>	<u>14,421</u>	<u>84,454</u>	<u>49,669</u>
			For the Six Months Ended June 30,	
			2026	2025
Net cash flows from operating activities			\$ 40,161	30,334
Net cash flows from investing activities			49,875	33,336
Net cash flows from financing activities			(215,018)	(195,056)
Effect of exchange rate changes on cash and cash equivalents			644	22,031
Net decrease in cash and cash equivalents			\$ <u>(124,338)</u>	<u>(109,355)</u>
Dividends paid to non-controlling interests			\$ <u>110,740</u>	<u>99,480</u>

2. Collective financial information of Arich and its subsidiaries:

	June 30, 2026	December 31, 2025	June 30, 2025
Current assets	\$ 4,475,339	4,518,404	4,984,173
Non-current assets	702,794	741,319	670,102
Current liabilities	(3,151,360)	(3,132,231)	(3,602,232)
Non-Current liabilities	(136,077)	(116,095)	(125,760)
Net assets	\$ <u>1,890,696</u>	<u>2,011,397</u>	<u>1,926,283</u>
Non-controlling interests	\$ <u>1,134,395</u>	<u>1,206,816</u>	<u>1,155,747</u>

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2026 AND 2025

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

	For the Three Months Ended June 30,		For the Six Months Ended June 30,	
	2026	2025	2026	2025
Operating revenue	\$ <u>376,229</u>	<u>378,713</u>	<u>787,610</u>	<u>772,514</u>
Net income	\$ 11,800	29,546	30,975	58,214
Other comprehensive (loss) income	(47,238)	41,245	(75,214)	35,826
Total comprehensive (loss) income	\$ <u>(35,438)</u>	<u>70,791</u>	<u>(44,239)</u>	<u>94,040</u>
Profit, attributable to non-controlling interests	\$ <u>7,080</u>	<u>17,728</u>	<u>18,585</u>	<u>34,929</u>
Comprehensive income, attributable to non-controlling interests	\$ <u>(32,767)</u>	<u>42,475</u>	<u>(26,543)</u>	<u>56,424</u>
	For the Six Months Ended June 30,		2026	2025
Net cash flows from operating activities			\$ 456,239	(1,422,572)
Net cash flows from investing activities			(21,528)	23,724
Net cash flows from financing activities			(420,226)	(117,490)
Net increase (decrease) in cash and cash equivalents			\$ <u>14,485</u>	<u>(1,516,338)</u>
Dividends paid to non-controlling interests			\$ <u>46,534</u>	<u>53,166</u>

3. Collective financial information of Asia Best Life Care investment and its subsidiaries:

	June 30, 2026
Current assets	\$ 1,259,170
Non-current assets	2,091,699
Current liabilities	(309,631)
Non-current liabilities	(1,051,727)
Net assets	\$ <u>1,989,511</u>
Non-controlling interests	\$ <u>1,011,235</u>
	For the Six Months Ended June 30,
	2026
Operating revenue	\$ <u>75,476</u>
Net income (loss)	\$ 4,251
Total comprehensive income	\$ <u>4,251</u>
Profit, attributable to non-controlling interests	\$ <u>2,167</u>
Comprehensive income, attributable to non-controlling interests	\$ <u>2,167</u>
Net cash flows from financing activities	\$ -
Dividends paid to non-controlling interests	\$ -

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2026 AND 2025

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

(j) Property, plant and equipment

The cost, depreciation, and impairment of the property, plant and equipment of the Group for the nine months ended June 30, 2026 and 2025 were as follows:

	Land	Buildings	Medical equipment	Miscellaneous equipment	Leased Improvement	Equipment to be inspected and construction in progress	Total
Cost or deemed cost:							
Balance as of January 1, 2026	\$ 148,747	248,433	497,824	604,782	15,726	45,613	1,561,125
Acquisition through business combination	-	-	12,696	65,913	270,762	-	349,371
Additions	-	-	10,366	19,708	68	34,715	64,857
Disposal and obsolescence	-	-	(6,981)	(16,742)	-	-	(23,723)
Transfer to inventories	-	-	(6,606)	(5,222)	-	-	(11,828)
Transfer from inventories	-	-	19,620	69	-	-	19,689
Reclassification	-	-	-	13,860	-	(34,529)	(20,669)
Effect of movements in exchange rates	756	1,790	(1,123)	910	-	(274)	2,059
Balance as of June 30, 2026	<u>\$ 149,503</u>	<u>250,223</u>	<u>525,796</u>	<u>683,278</u>	<u>286,556</u>	<u>45,525</u>	<u>1,940,881</u>
Balance as of January 1, 2025	\$ 144,507	238,277	539,855	563,532	15,726	39,018	1,540,915
Additions	-	-	10,083	29,570	-	18,817	58,470
Disposal and obsolescence	-	-	(34,394)	(19,610)	-	(7,868)	(61,872)
Transfer from inventories	-	-	39,550	12,917	-	-	52,467
Transfer to inventories	-	-	(8,414)	(1,778)	-	-	(10,192)
Transfer from prepayments	-	-	12,381	-	-	-	12,381
Reclassification	-	-	(1,128)	8,614	-	(7,963)	(477)
Effect of movements in exchange rates	(3,830)	(9,051)	(9,105)	(1,874)	-	(2,898)	(26,758)
Balance as of June 30, 2025	<u>\$ 140,677</u>	<u>229,226</u>	<u>548,828</u>	<u>591,371</u>	<u>15,726</u>	<u>39,106</u>	<u>1,564,934</u>
Depreciation and impairment losses:							
Balance as of January 1, 2026	\$ 4,000	82,825	266,827	445,518	5,950	-	805,120
Acquisition through business combination	-	-	6,275	40,854	112,246	-	159,375
Depreciation for the period	-	3,598	35,632	41,633	3,000	-	83,863
Disposal and obsolescence	-	-	(6,981)	(16,742)	-	-	(23,723)
Transfer to inventories	-	-	(784)	(4,930)	-	-	(5,714)
Effect of movements in exchange rates	-	485	(443)	958	-	-	1,000
Balance as of June 30, 2026	<u>\$ 4,000</u>	<u>86,908</u>	<u>300,526</u>	<u>507,291</u>	<u>121,196</u>	<u>-</u>	<u>1,019,921</u>
Balance as of January 1, 2025	\$ 4,000	75,608	284,765	377,414	3,531	-	745,318
Depreciation for the period	-	2,272	38,365	47,187	1,209	-	89,033
Disposal and obsolescence	-	-	(13,190)	(19,610)	-	-	(32,800)
Transfer to inventories	-	-	(2,793)	(1,122)	-	-	(3,915)
Effect of movements in exchange rates	-	(2,722)	(6,340)	529	-	-	(8,533)
Balance as of June 30, 2025	<u>\$ 4,000</u>	<u>75,158</u>	<u>300,807</u>	<u>404,398</u>	<u>4,740</u>	<u>-</u>	<u>789,103</u>
Carrying amount:							
Balance as of January 1, 2025	<u>\$ 144,747</u>	<u>165,608</u>	<u>230,997</u>	<u>159,264</u>	<u>9,776</u>	<u>45,613</u>	<u>756,005</u>
Balance as of June 30, 2026	<u>\$ 145,503</u>	<u>163,315</u>	<u>225,270</u>	<u>175,987</u>	<u>165,360</u>	<u>45,525</u>	<u>920,960</u>
Balance as of January 1, 2025	<u>\$ 140,507</u>	<u>162,669</u>	<u>255,090</u>	<u>186,118</u>	<u>12,195</u>	<u>39,018</u>	<u>795,597</u>
Balance as of June 30, 2025	<u>\$ 136,677</u>	<u>154,068</u>	<u>248,021</u>	<u>186,973</u>	<u>10,986</u>	<u>39,106</u>	<u>775,831</u>

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2026 AND 2025

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

Please refer to Note 6(h) for information on the property, plant and equipment of Asia Best Life Care Co., Ltd. acquired by the Group through the merger on May 29, 2026.

For the six-month periods ended June 30, 2026 and 2025, none of the Group's property, plant and equipment was pledged as collateral.

(k) Right-of-use assets

The Group leases many assets including buildings, machinery and other equipment. Information about leases for which the Group as a lessee was presented below:

	<u>Land</u>	<u>Buildings</u>	<u>Machinery and equipment</u>	<u>Other equipment</u>	<u>Total</u>
Cost:					
Balance as of January 1, 2026	\$ -	592,254	10,027	404	602,685
Acquisition through business combination	8,735	824,102	-	3,912	836,749
Additions	-	144,593	-	-	144,593
Write-off	-	(33,867)	-	-	(33,867)
Effect of movements in exchange rates	-	(1,308)	-	(11)	(1,319)
Balance as of June 30, 2026	<u>\$ 8,735</u>	<u>1,525,774</u>	<u>10,027</u>	<u>4,305</u>	<u>1,548,841</u>
Balance as of January 1, 2025	\$ -	551,249	7,737	-	558,986
Additions	-	27,138	4,539	422	32,099
Write-off	-	(25,530)	-	-	(25,530)
Effect of movements in exchange rates	-	(2,783)	-	(27)	(2,810)
Balance as of June 30, 2025	<u>\$ -</u>	<u>550,074</u>	<u>12,276</u>	<u>395</u>	<u>562,745</u>
Accumulated depreciation and impairment losses:					
Balance as of January 1, 2026	\$ -	325,789	4,587	195	330,571
Acquisition through business combination	962	176,017	-	1,799	178,778
Depreciation for the year	36	69,733	1,563	222	71,554
Write-off	-	(20,399)	-	-	(20,399)
Effect of movements in exchange rates	-	(327)	-	(8)	(335)
Balance as of June 30, 2026	<u>\$ 998</u>	<u>550,813</u>	<u>6,150</u>	<u>2,208</u>	<u>560,169</u>
Balance as of January 1, 2025	\$ -	229,593	3,774	-	233,367
Depreciation for the year	-	55,583	1,499	47	57,129
Write-off	-	(10,669)	-	-	(10,669)
Effect of movements in exchange rates	-	(522)	-	(3)	(525)
Balance as of June 30, 2025	<u>\$ -</u>	<u>273,985</u>	<u>5,273</u>	<u>44</u>	<u>279,302</u>

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2026 AND 2025

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

	<u>Land</u>	<u>Buildings</u>	<u>Machinery and equipment</u>	<u>Other equipment</u>	<u>Total</u>
Carrying amount:					
Balance as of January 1, 2026	\$ -	266,465	5,440	209	272,114
Balance as of June 30, 2026	\$ 7,737	974,961	3,877	2,097	988,672
Balance as of January 1, 2025	\$ -	321,656	3,963	-	325,619
Balance as of June 30, 2025	\$ -	276,089	7,003	351	283,443

For the six months ended June 30, 2026 and 2025, the Group leases storage room, machinery and parking space under operating lease, please refer to Note (6)(r).

Please refer to Note 6(h) for information on the right-of-use assets of Asia Best Life Care Co., Ltd. acquired by the Group through the merger on May 29, 2026.

(l) Investment property

Investment properties are the assets hold by the Group. The period of rental investment properties that cannot be terminated originally is 15 years.

	<u>Owned property</u>		<u>Total</u>
	<u>Land</u>	<u>Buildings</u>	
Book value:			
Balance at January 1, 2026	\$ 1,266,920	331,322	1,598,242
Balance as of June 30, 2026	\$ 1,266,920	325,170	1,592,090
Balance as of January 1, 2025	\$ 1,266,920	343,625	1,610,545
Balance as of June 30, 2025	\$ 1,266,920	337,474	1,604,394

The fair value of investment properties was based on a valuation by a qualified independent appraiser. Fair value was measured using comparison approach, income approach and cost approach.

As of June 30, 2026, December 31, 2025 and June 30, 2025, the investment property of the Group had been pledged as collateral , please refer to Note (8).

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2026 AND 2025

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

(m) Intangible assets

	<u>Goodwill</u>	<u>Software</u>	<u>Other intangible assets</u>	<u>Total</u>
Cost:				
Balance as of January 1, 2026	\$ 64,552	26,885	31,680	123,117
Additions	-	1,083	-	1,083
Acquisition through business combinations	170,116	16,645	-	186,761
Effect of movements in exchange rates	<u>395</u>	<u>(67)</u>	<u>-</u>	<u>328</u>
Balance as of June 30, 2026	<u><u>\$ 235,063</u></u>	<u><u>44,546</u></u>	<u><u>31,680</u></u>	<u><u>311,289</u></u>
Balance as of January 1, 2025	\$ 59,540	24,783	31,680	116,003
Additions	-	1,688	-	1,688
Disposals	-	(3,010)	-	(3,010)
Effect of movements in exchange rates	<u>793</u>	<u>(197)</u>	<u>-</u>	<u>596</u>
Balance as of June 30, 2025	<u><u>\$ 60,333</u></u>	<u><u>23,264</u></u>	<u><u>31,680</u></u>	<u><u>115,277</u></u>
Amortization and impairment loss:				
Balance as of January 1, 2026	\$ 35,163	17,310	23,887	76,360
Amortization	-	2,701	712	3,413
Acquisition through business combinations	871	12,818	-	13,689
Effect of movements in exchange rates	<u>316</u>	<u>(31)</u>	<u>-</u>	<u>285</u>
Balance as of June 30, 2026	<u><u>\$ 36,350</u></u>	<u><u>32,798</u></u>	<u><u>24,599</u></u>	<u><u>93,747</u></u>
Balance as of January 1, 2025	\$ 30,595	16,021	22,263	68,879
Amortization	-	1,985	812	2,797
Disposals	-	(3,010)	-	(3,010)
Effect of movements in exchange rates	<u>1,194</u>	<u>(68)</u>	<u>-</u>	<u>1,126</u>
Balance as of June 30, 2025	<u><u>\$ 31,789</u></u>	<u><u>14,928</u></u>	<u><u>23,075</u></u>	<u><u>69,792</u></u>
Book value:				
Balance as of January 1, 2026	<u><u>\$ 29,389</u></u>	<u><u>9,575</u></u>	<u><u>7,793</u></u>	<u><u>46,757</u></u>
Balance as of June 30, 2026	<u><u>\$ 198,713</u></u>	<u><u>11,748</u></u>	<u><u>7,081</u></u>	<u><u>217,542</u></u>
Balance as of January 1, 2025	<u><u>\$ 28,945</u></u>	<u><u>8,762</u></u>	<u><u>9,417</u></u>	<u><u>47,124</u></u>
Balance as of June 30, 2025	<u><u>\$ 28,544</u></u>	<u><u>8,336</u></u>	<u><u>8,605</u></u>	<u><u>45,485</u></u>

Please refer to Note 6(h) for information on the intangible assets of Asia Best Life Care Co., Ltd. acquired by the Group through the merger on May 29, 2026.

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2026 AND 2025

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

(n) Long and short-term borrowings

	June 30, 2026	December 31, 2025	June 30, 2025
Secured bank loans	\$ 700,000	732,000	767,000
Unsecured bank loans	291,550	961,221	405,216
Total	<u>\$ 991,550</u>	<u>1,693,221</u>	<u>1,172,216</u>
Unused credit lines	<u>\$ 4,541,651</u>	<u>3,446,199</u>	<u>4,039,826</u>
Range of interest rates	<u>1.82%~4.38%</u>	<u>1.73%~6.45%</u>	<u>1.71%~6.50%</u>

Please refer to Note (8) for details of the Group's assets pledged as collateral for bank borrowings.

The Group's interest risk and sensitivity analysis of financial assets and liabilities were disclosed in Note (6)(aa).

(o) Other payables

	June 30, 2026	December 31, 2025	June 30, 2025
Logistics services payable	\$ 2,435,082	2,110,545	3,128,195
Dividend payable	95,783	-	27,429
Others	575,341	485,784	464,313
	<u>\$ 3,106,206</u>	<u>2,596,329</u>	<u>3,619,937</u>

(p) Provisions

	June 30, 2026	December 31, 2025	June 30, 2025
Warranties	<u>\$ 14,183</u>	<u>16,628</u>	<u>16,740</u>
			Warranties
Balance as of January 1, 2026			\$ 16,628
Additions			6,029
Provisions reversed or used			(8,474)
Balance as of June 30, 2026			<u>\$ 14,183</u>
Balance as of January 1, 2025			\$ 18,241
Additions			7,066
Provisions reversed or used			(8,567)
Balance as of June 30, 2025			<u>\$ 16,740</u>

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2026 AND 2025

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

Warranties

The provision for warranty claims represents the present value of management's best estimate of the future outflow of economic benefits that will be required under the Group's obligations for warranties under local sale of goods legislation. The estimate had been made on the basis of historical warranty trends and may vary as a result of other events affecting product quality.

(q) Lease liabilities

The carrying amounts of lease liabilities were as follows:

	June 30, 2026	December 31, 2025	June 30, 2025
Current	\$ <u>241,581</u>	<u>140,406</u>	<u>127,679</u>
Non-current	\$ <u>1,177,157</u>	<u>320,279</u>	<u>339,583</u>

For the maturities analysis, please refer to Note (6)(aa).

The amounts recognized in profit or loss were as follows:

	For the Three Months Ended June 30, 2026	2025	For the Six Months Ended June 30, 2026	2025
Interest on lease liabilities	\$ <u>3,221</u>	<u>1,941</u>	<u>5,371</u>	<u>3,963</u>
Income from sub-leasing right-of-use assets	\$ <u>16,459</u>	<u>4,283</u>	<u>24,842</u>	<u>8,125</u>
Expenses relating to short- term leases	\$ <u>3,522</u>	<u>3,295</u>	<u>5,536</u>	<u>6,509</u>

The amounts recognized in the statement of cash flows for the Group were as follows:

	For the Six Months Ended June 30, 2026	2025
Total cash outflow for leases	\$ <u>98,109</u>	<u>77,999</u>

1. Buildings leases

The Group leases buildings for its office space. The leases of office space typically run for a period of 2 to 10 years. Some leases include an option to renew the lease for an additional period of the same duration after the end of the contract term.

The Group sub-leases some of its right-of-use assets under operating leases; please refer to Note (6)(r).

2. Other leases

The Group leases machinery and other equipment, with lease terms of 1 to 10 years. In some cases, the Group has options to purchase the assets at the end of the contract term.

The Group also leases storage room, machinery and parking space with contract terms of 1 year to 3 years. These leases are short-term or leases of low-value items. The Group has elected not to recognize right-of-use assets and lease liabilities for these leases.

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2026 AND 2025

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

(r) Operating leases

Operating leases relate to leases and subleases of housing and leases of equipments with lease terms between 1 to 10 years. The leasees does not have bargain purchase options to acquire the leased housing and equipments at the expiration of the lease periods.

A maturity analysis of lease payments, showing the undiscounted lease payments to be received after the reporting date are as follows:

	June 30, 2026	December 31, 2025	June 30, 2025
Within 1 year	\$ 6,323	11,541	6,419
1 to 5 years	923	1,403	257
More than 5 years	-	-	-
	<u>\$ 7,246</u>	<u>12,944</u>	<u>6,676</u>

(s) Employee benefits

1. Defined benefit plans

Management believes that there was no material volatility of the market, no material reimbursement and settlement or other material one time events since prior fiscal year. As a result, the pension cost in the accompanying interim period was measured and disclosed according to the actuarial report as of December 31, 2025 and 2024.

The expenses recognized in profit or loss for the Group were as follows:

	For the Three Months Ended June 30, 2026	2025	For the Six Months Ended June 30, 2026	2025
Operating costs and expenses	\$ 237	156	468	306

2. Defined contribution plans

The Group's expenses for the pension plan contributions to the Bureau of Labor Insurance for the three months ended June 30, 2026 and 2025 and for the six months ended June 30, 2026 and 2025 were as follows:

	For the Three Months Ended June 30, 2026	2025	For the Six Months Ended June 30, 2026	2025
Operating costs and expenses	\$ 7,250	8,574	16,222	16,896

3. The foreign Company's pension costs under the local laws were \$694 thousand, \$677 thousand, \$1,701 thousand and \$1,588 thousand for the three months ended June 30, 2026 and 2025 and for the six months ended June 30, 2026 and 2025, respectively.

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2026 AND 2025

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

(t) Income taxes

The components of income tax were as follows:

	For the Three Months Ended June 30,		For the Six Months Ended June 30,	
	2026	2025	2026	2025
Current tax expense				
Current period	\$ 65,853	51,228	124,654	110,999
Adjustment for prior periods	(2,498)	870	(3,062)	870
	<u>63,355</u>	<u>52,098</u>	<u>121,592</u>	<u>111,869</u>
Deferred tax expense				
Current period	6,576	5,086	5,769	2,345
Prior period underestimate	<u>2,480</u>	<u>1,815</u>	<u>2,480</u>	<u>1,815</u>
Income tax expense from continuing operations	<u>\$ 72,411</u>	<u>58,999</u>	<u>129,841</u>	<u>116,029</u>

The amount of income tax recognized directly in equity for 2026 was as follows; no income tax was recognized directly in equity for 2025:

	For the Three Months Ended June 30,		For the Six Months Ended June 30,	
	2026	2025	2026	2025
Gain on disposal of foreign listed shares	<u>\$ 2,146</u>	<u>-</u>	<u>14,378</u>	<u>-</u>

The amounts of income tax recognized in other comprehensive income for the three months ended June 30, 2026 and 2025 and for the six months ended June 30, 2026 and 2025 were as follows:

	For the Three Months Ended June 30,		For the Six Months Ended June 30,	
	2026	2025	2026	2025
Items that will not be reclassified subsequently to profit or loss:				
Unrealized gains (losses) on equity instruments at fair value through other comprehensive income	<u>\$ (22,086)</u>	<u>17,389</u>	<u>(18,239)</u>	<u>13,037</u>
Items that may be reclassified subsequently to profit or loss:				
Exchange differences on translation	<u>\$ (41)</u>	<u>(1,569)</u>	<u>126</u>	<u>(1,591)</u>

The Company's income tax returns for the years through 2024 were assessed by the Tax Administration.

(u) Capital and other equity

Except for the following disclosure, there was no significant change in capital and other equity for the periods from for the six months ended June 30, 2026 and 2025. For the related information, please refer to note (6)(t) to the consolidated financial statements for the year ended December 31, 2025.

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2026 AND 2025

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

1.Share capital

	June 30, 2026	December 31, 2025	June 30, 2025
Number of shares authorized (in thousands)	<u>200,000</u>	<u>200,000</u>	<u>200,000</u>
Shares authorized	<u>\$ 2,000,000</u>	<u>2,000,000</u>	<u>2,000,000</u>
Number of shares issued and fully paid (in thousands)	<u>188,367</u>	<u>171,567</u>	<u>163,398</u>
Shares issued	<u>\$ 1,883,674</u>	<u>1,715,674</u>	<u>1,633,975</u>

On November 7, 2025, the Board of Directors passed a resolution to issue 16,800 thousand shares of common stock for the capital increase in cash, with a par value of NTD10 per share, including 2,520 thousand shares subscribed by employees and 1,680 thousand shares for public offerings, at an issue price of \$ 60 per share. This capital increase was reported by the competent authority and took effect on December 22, 2025. The total cash subscription proceeds of \$1,080,000 thousand have been received in full. The base date of the capital increase is January 29, 2026. All relevant statutory registration procedures have been completed as of the reporting date.

The Company issued 8,170 thousand common shares amounting to \$81,699 thousand, with the date of capital increase set on September 9, 2025, based on the resolution decided during the shareholders' meeting held on June 26, 2025, and the approval of the Financial Supervisory Commission, R.O.C. on August 18, 2025. All relevant statutory registration procedures have been completed as of the reporting date.

A total of 10,000 thousand shares of the Company's authorized shares are reserved for the issuance of employee share options, convertible bonds with warrants and preferred shares with warrants.

2.Capital surplus

	June 30, 2026	December 31, 2025	June 30, 2025
Additional paid-in capital arising from ordinary share	\$ 2,662,584	1,822,584	1,822,584
Additional paid-in capital arising from bond conversion	1,072,079	1,072,079	1,072,079
Difference between consideration and carrying amount of subsidiaries acquired or disposed	193,054	193,054	193,054
Changes in ownership interest in subsidiaries	250,941	250,941	250,872
Changes in equity of associates accounted for using equity method	8,315	8,315	339
Employee share options	18,152	-	-
Others	43,860	43,860	43,860
	<u>\$ 4,248,985</u>	<u>3,390,833</u>	<u>3,382,788</u>

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2026 AND 2025

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

3. Retained earnings

The Company's article of incorporation stipulates that Company's profit after tax should first be used to offset the prior years' deficits, including adjustment of unappropriated retained earnings and 10% of the rest be set aside as legal reserve, then the special surplus reserve shall be distributed or reversed according to the Laws acts and regulations approved by the Competent authority. The remainder, together with any undistributed retained earnings, including amount of adjusted retained earnings, shall be distributed by the Board of Directors and submitted to the stockholders' meeting for approval. The distribution of dividends, bonus, legal reserve and capital surplus, distributed by way of cash, shall be decided during the Board meeting, approved by more than half of the directors, with two thirds of directors in attendance; thereafter, to be submitted in the shareholders' meeting of the Company.

The Company's Articles also stipulate a dividend policy which is as follows: According to the present and future development plans, the investment environment, capital requirements, domestic and overseas competition, and the benefit of shareholders, the Company should distribute dividends and bonuses to shareholders at no less than 20% of the remaining profit (which is the current net profit less losses of previous years, less the adjustment to retained earnings, and less 10% of its after-tax annual earnings as legal reserve). Dividends could be distributed in cash or shares, where cash dividends should not be less than 20% of the total dividends distributed.

According to the amendment of the R.O.C. Company Act in January 2012, the Company must retain 10% of its after-tax annual earnings as legal reserve until such retention equals the amount of total capital. When a company incurs no loss, it may, pursuant to a resolution by a shareholders' meeting, distribute its legal reserve by issuing new shares or by distributing cash, and only the portion of legal reserve which exceeds 25% of capital may be distributed.

The amount of cash dividends on the appropriations of earnings for 2025 and 2024 had been approved during the board meeting on March 6, 2026 and March 7, 2025. The amount of shares dividends of appropriation of earnings for 2024 has been approved during the shareholders' meeting on June 26, 2025, as follows:

	2025		2024	
	Dividend per share (\$)	Amount	Dividend per share (\$)	Amount
Dividends distributed to common shareholders				
Cash	\$ 4.30	809,980	3.80	620,910
Share	-	-	0.50	81,699
Total		\$ 809,980		702,609

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2026 AND 2025

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

4. Other equity interest after tax

	Exchange differences on translation of foreign financial statements	Unrealized gains (losses) from financial assets measured at fair value through other comprehensive income
Balance as of January 1, 2026	\$ (43,667)	388,612
Exchange differences on translation of foreign financial statement	30,001	-
Exchange differences on associates accounted for using equity method	(8,714)	-
Unrealized losses from financial assets measured at fair value through other comprehensive income	-	(31,710)
Unrealized losses from financial assets measured at fair value through other comprehensive income, associates accounted for using equity method	-	(98,221)
Disposal of investments in equity instruments designated at fair value through other comprehensive income	-	(19,534)
Balance as of June 30, 2026	<u>\$ (22,380)</u>	<u>239,147</u>
Balance as of January 1, 2025	\$ (10,729)	344,217
Exchange differences on translation of foreign financial statement	(306,641)	-
Exchange differences on associates accounted for using equity method	36,760	-
Unrealized gains from financial assets measured at fair value through other comprehensive income	-	4,119
Unrealized losses from financial assets measured at fair value through other comprehensive income, associates accounted for using equity method	-	(23,354)
Balance as of June 30, 2025	<u>\$ (280,610)</u>	<u>324,982</u>

5. Non-controlling interests after tax

	For the Six Months Ended June 30,	
	2026	2025
Balance, beginning of year	\$ 2,532,320	2,387,112
Shares attributed to non-controlling interests		
Net income	68,389	88,300
Exchange differences on translation of foreign financial statements	(23,573)	(36,202)
Unrealized gains or losses from financial assets measured at fair value through other comprehensive income	(44,130)	31,034
Change in equity of subsidiaries accounted for under equity method	2,912	-
Cash dividends of subsidiaries distributed to non controlling interests	(157,274)	(152,646)
Acquired the non-controlling interests from the acquisition of subsidiaries	1,012,085	-
Balance, end of year	<u>\$ 3,390,729</u>	<u>2,317,598</u>

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2026 AND 2025

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

(v) Share-based payments

On November 7, 2025, the Board of Directors passed a resolution to issue common stock for the capital increase in cash, and reserved a portion of the shares for employee subscription, with a par value of \$10 per share. The eligible recipients were limited to full-time employees of the Group and its subsidiaries who met specified conditions. This capital increase was reported by Financial Supervisory Commission R.O.C(Taiwan) and took effect.

1. Expense recognized in profit or loss and liabilities

The Group incurred expenses related to share-based payments for the six months ended June 30, 2026, as follows:

	For the Three Months Ended June 30, 2026	For the Six Months Ended June 30, 2026
Expenses resulting from cash-settled share-based payment to employees	\$ -	21,064

(w) Earnings per share

For the three months ended June 30, 2026 and 2025 and for the six months ended June 30, 2026 and 2025, the basic and diluted earnings per share were calculated as follows:

1. Basic earnings per share

	For the Three Months Ended June 30, 2026	2025	For the Six Months Ended June 30, 2026	2025
Profit attributable to ordinary shareholders of the Company	\$ 308,497	229,822	513,677	425,065
Weighted average number of ordinary shares (basic)(retroactive adjustments)	185,769	163,398	185,769	163,398

2. Diluted earnings per share

	For the Three Months Ended June 30, 2026	2025	For the Six Months Ended June 30, 2026	2025
Profit attributable to ordinary shareholders of the Company	\$ 308,497	229,822	513,677	425,065
Weighted average number of ordinary shares (basic)(retroactive adjustments)	185,769	163,398	185,769	163,398
Effect of employee stock compensation	470	312	702	512
Weighted average number of ordinary shares (diluted)(retroactive adjustments)	186,239	163,710	186,471	163,910

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2026 AND 2025

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

(x) Revenue from contracts with customers

1. Disaggregation of revenue

	For the Three Months Ended June 30,		For the Six Months Ended June 30,	
	2026	2025	2026	2025
Primary geographical markets:				
Taiwan	\$ 2,043,001	2,035,189	4,170,593	4,052,646
Hong Kong	-	1,730	3,515	2,784
China	4,686	3,366	5,561	10,402
Philippines	294,352	97,043	469,300	186,731
Malaysia	35,388	16,896	57,925	33,621
Indonesia	8,817	13,425	22,308	30,790
	<u>\$ 2,386,244</u>	<u>2,167,649</u>	<u>4,729,202</u>	<u>4,316,974</u>
Major products:				
Product revenue				
Medical equipment and Supplies	\$ 1,381,033	1,235,215	2,767,928	2,455,787
Medicines	307,937	278,325	650,044	595,016
Aesthetic medical equipment and Supplies	241,282	223,828	482,333	481,662
Household appliances	45,345	37,993	82,537	72,783
Long-term care, home care and respite care services	55,716	-	55,716	-
Other	22,373	38,806	45,507	51,595
Repair and maintenance revenue	152,855	150,161	301,176	289,743
Other operating revenue	179,703	203,321	343,961	370,388
	<u>\$ 2,386,244</u>	<u>2,167,649</u>	<u>4,729,202</u>	<u>4,316,974</u>

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2026 AND 2025

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

2.Contract balances

	June 30, 2026	December 31, 2025	June 30, 2025
Notes receivable, accounts receivable, lease payment receivable and other receivables	\$ 6,712,979	5,597,677	6,111,036
Less: allowance for impairment	(61,408)	(55,766)	(53,539)
Total	<u>\$ 6,651,571</u>	<u>5,541,911</u>	<u>6,057,497</u>
Contract liabilities	<u>\$ 545,483</u>	<u>572,217</u>	<u>534,663</u>

For details on trade receivables and allowance for impairment, please refer to note (6)(e).

The amount of revenue recognized for the three months ended June 30, 2026 and 2025 and for the six months ended June 30, 2026 and 2025 that was included in the contract liability balance at the beginning of the period were \$65,259 thousand, \$99,553 thousand, \$144,887 thousand and \$168,061 thousand, respectively.

(y) Employee compensation and directors' remuneration

On June 26, 2025, the Company resolved at the shareholders' meeting to amend its Articles of Incorporation. According to the amended Company Article of Incorporation, if the Company incurs profit for the year, the profit shall first be used to offset against any accumulated deficits. Thereafter, a maximum of 5% of the remaining net profit shall be allocated as directors' remuneration in cash, and no less than 1% (in shares or in cash) as employee remuneration. (At least 30% shall be allocated for salary adjustments or remuneration distributions for its non executive employees.) The distribution shall also include those employees of the Company's subsidiaries who meet certain requirements.

Prior to the amendment, the Articles of Incorporation stipulated that, if the Company incurs profit for the year, the profit shall first be used to offset against any accumulated deficits. Thereafter, a maximum of 5% of the remaining net profit shall be allocated as directors' remuneration in cash, and a minimum of 1% (in shares or in cash) as employee remuneration, including those employees of the Company's subsidiaries who meet certain requirements.

For the three months ended June 30, 2026 and 2025 and for the six months ended June 30, 2026 and 2025, the Company estimated its employee compensation amounting to \$19,315 thousand, \$14,180 thousand, \$32,289 thousand and \$26,432 thousand, and directors' remuneration amounting to \$9,657 thousand, \$7,090 thousand, \$16,144 thousand and \$13,216 thousand, respectively. The estimated amounts mentioned above are calculated based on the net profit before tax, excluding the compensation to employees and remuneration to directors of each period, multiplied by the percentage specified in the Company's articles. These remunerations were expensed under operating costs or expenses for each period. If there are any subsequent adjustments to the actual remuneration amounts after the annual shareholders' meeting, the adjustments will be regarded as changes in accounting estimates and will be reflected in profit or loss in the following year.

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2026 AND 2025

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

For the years ended December 31, 2025 and 2024, the compensation to employees which were paid in cash, amounted to \$50,271 thousand and \$47,985 thousand, respectively and directors' remuneration paid in cash, amounted to \$25,136 thousand and \$23,992 thousand, respectively. The information is available on the Market Observation Post System website.

(z) Non-operating income and expenses

1. Interest Income

The details of other income were as follows:

	For the Three Months Ended June 30,		For the Six Months Ended June 30,	
	2026	2025	2026	2025
Interest income from bank deposits	\$ 14,036	13,248	25,184	32,237
Interest income from lease payment receivable	7,566	4,793	14,776	9,127
Total	<u>\$ 21,602</u>	<u>18,041</u>	<u>39,960</u>	<u>41,364</u>

2. Other income

The details of other income were as follows:

	For the Three Months Ended June 30,		For the Six Months Ended June 30,	
	2026	2025	2026	2025
Dividend income	\$ 12	1,577	624	1,577
Other income	650	1,154	1,725	1,771
	<u>\$ 662</u>	<u>2,731</u>	<u>2,349</u>	<u>3,348</u>

3. Financial costs

The details of financial costs were as follows:

	For the Three Months Ended June 30,		For the Six Months Ended June 30,	
	2026	2025	2026	2025
Bank borrowings	\$ 5,064	5,367	9,728	11,049
Others	4,262	2,808	7,651	5,708
	<u>\$ 9,326</u>	<u>8,175</u>	<u>17,379</u>	<u>16,757</u>

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2026 AND 2025

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

4. Other gains and losses

The details of other gains and losses were as follows:

	For the Three Months Ended June 30,		For the Six Months Ended June 30,	
	2026	2025	2026	2025
Gains (losses) on disposal of property, plant, and equipment	\$ -	(7)	54	406
Gains on disposals of investments	71,120	-	71,120	-
Foreign exchange losses	(1,537)	(14,511)	(4,091)	(10,012)
Net gains or losses on financial assets (liabilities) measured at fair value through profit or loss	(750)	(3,807)	(296)	(2,545)
Others	6,461	(222)	7,105	353
	\$ 75,294	(18,547)	73,892	(11,798)

(aa) Financial instruments

Except for the contention mentioned below, there was no significant change in the fair value of the Group's financial instruments and degree of exposure to credit risk arising from financial instruments. For related information, please refer to note (6)(y) to the consolidated financial statements for the year ended December 31, 2025.

1. Liquidity risks

The following are the contractual maturities of financial liabilities of the Group, including estimated interest payments and excluding the impact of netting arrangements:

	Carrying amount	Contractual cash flow	On Demand or Less than 1 month	1-3 months	3-6 months	6-12 months	1-2 years	More than 2 years
June 30, 2026								
Non-derivative financial liabilities								
Short-term borrowings	\$ 641,550	644,023	350,566	41,550	251,907	-	-	-
Payables	4,129,094	4,129,094	895,217	3,051,752	62,298	119,827	-	-
Lease liabilities	1,418,738	1,512,735	52,937	25,355	38,037	91,568	173,168	1,131,670
Long-term borrowings	350,000	479,372	583	1,166	1,748	3,497	6,993	465,385
Deposits received	54,386	54,386	194	-	-	-	-	54,192
Derivative financial liabilities								
Foreign exchange forward contracts:								
Outflows	28,177	28,177	-	28,177	-	-	-	-
Inflows	(28,492)	(28,492)	-	(28,492)	-	-	-	-
	\$ 6,593,453	6,819,295	1,299,497	3,119,508	353,990	214,892	180,161	1,651,247

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2026 AND 2025

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

	Carrying amount	Contractual cash flow	On Demand or Less than 1 month	1-3 months	3-6 months	6-12 months	1-2 years	More than 2 years
December 31, 2025								
Non-derivative financial liabilities								
Short-term borrowings	\$ 1,343,221	1,344,055	950,236	393,819	-	-	-	-
Payables	3,742,683	3,742,683	819,879	2,797,534	38,303	86,967	-	-
Lease liabilities	460,685	462,806	12,224	23,547	35,334	70,347	91,710	229,644
Long-term borrowings	350,000	482,868	583	1,166	1,748	3,497	6,993	468,881
Deposits received	9,513	9,513	-	-	-	-	-	9,513
	<u>\$ 5,906,102</u>	<u>6,041,925</u>	<u>1,782,922</u>	<u>3,216,066</u>	<u>75,385</u>	<u>160,811</u>	<u>98,703</u>	<u>708,038</u>
June 30, 2025								
Non-derivative financial liabilities								
Short-term borrowings	\$ 822,216	823,115	105,738	717,377	-	-	-	-
Payables	4,678,221	4,678,221	780,654	3,761,231	52,329	84,007	-	-
Lease liabilities	467,262	484,875	12,280	22,084	33,444	65,529	104,617	246,921
Long-term borrowings	350,000	493,366	-	-	-	-	-	493,366
Deposits received	11,124	11,124	-	-	-	-	-	11,124
Derivative financial liabilities								
Foreign exchange forward contracts:								
Outflows	47,497	47,497	-	47,497	-	-	-	-
Inflows	(46,377)	(46,377)	-	(46,377)	-	-	-	-
	<u>\$ 6,329,943</u>	<u>6,491,821</u>	<u>898,672</u>	<u>4,501,812</u>	<u>85,773</u>	<u>149,536</u>	<u>104,617</u>	<u>751,411</u>

The Group is not expecting that the cash flows included in the maturity analysis could occur significantly earlier or at significantly different amounts.

2. Market risks

1) Currency risks

The Group's significant exposure to foreign currency risk of financial assets and liabilities were as follows:

Functional currency	Exchange rate	Currency	June 30, 2026	
			Foreign currency (in thousands)	Carrying amount (TWD)
<u>Financial assets</u>				
<u>Monetary items</u>				
TWD	31.850	USD	\$ 6,830	217,539
TWD	0.197	JPY	240,815	47,344
TWD	36.310	EUR	245	8,890
HKD	7.836	USD	1,487	47,358
USD	4.216	MYR	404	12,868

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2026 AND 2025

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

			June 30, 2026	
	Exchange rate	Currency	Foreign currency (in thousands)	Carrying amount (TWD)
Functional currency				
<u>Non-Monetary items</u>				
TWD	0.022	KRW	7,084,022	146,639
USD	0.031	TWD	778,143	778,143
USD	0.147	CNY	6,674	31,311
USD	0.128	HKD	263,318	1,090,461
USD	0.237	MYR	42,838	323,631
USD	0.016	PHP	503,875	261,589
<u>Financial liabilities</u>				
<u>Monetary items</u>				
TWD	0.197	JPY	276,600	54,380
TWD	31.850	USD	1,540	49,042
TWD	36.310	EUR	146	5,301
USD	61.321	PHP	1,078	34,334
			December 31, 2025	
	Exchange rate	Currency	Foreign currency (in thousands)	Carrying amount (TWD)
Functional currency				
<u>Financial assets</u>				
<u>Monetary items</u>				
TWD	31.430	USD	\$ 3,647	114,622
TWD	0.201	JPY	63,280	12,706
HKD	4.038	USD	11,835	371,969
MYR	4.202	USD	573	18,010
<u>Non-Monetary items</u>				
TWD	0.022	KRW	10,415,732	229,146
USD	0.032	TWD	732,962	732,962
USD	0.143	CNY	6,747	30,326
USD	0.129	HKD	249,794	1,008,855
USD	0.238	MYR	43,086	322,296
USD	0.017	PHP	289,392	154,625

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2026 AND 2025

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

			December 31, 2025	
Functional currency	Exchange rate	Currency	Foreign currency (in thousands)	Carrying amount (TWD)
Financial liabilities				
Monetary items				
TWD	0.201	JPY	290,667	58,366
TWD	31.430	USD	1,590	49,973
PHP	58.913	USD	1,769	55,600
			June 30, 2025	
Functional currency	Exchange rate	Currency	Foreign currency (in thousands)	Carrying amount (TWD)
Financial assets				
Monetary items				
TWD	29.300	USD	\$ 3,198	93,699
TWD	0.203	JPY	25,339	5,154
TWD	34.350	EUR	30	1,033
HKD	7.851	USD	1,560	45,703
MYR	4.379	USD	757	22,181
Non-Monetary items				
TWD	0.022	KRW	5,908,125	129,270
USD	0.034	TWD	695,749	695,749
USD	0.140	CNY	6,216	25,424
USD	0.127	HKD	259,247	967,721
USD	0.228	MYR	43,779	292,846
USD	0.018	PHP	223,857	116,750
Financial liabilities				
Monetary items				
TWD	0.203	JPY	223,151	45,389
TWD	29.300	USD	873	25,578
PHP	56.314	USD	1,342	39,321

Since the Group has many kinds of currency, the information on foreign exchange gains or losses on monetary items is disclosed by total amount. For the six months ended June 30, 2026 and 2025, foreign exchange gains or losses amounted to gains of \$4,091 thousand and gains of \$10,012 thousand, respectively.

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2026 AND 2025

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

2) Sensitivity analysis

The Group's foreign exchange exposure to foreign currency risk arises from foreign currency exchange fluctuations on cash and cash equivalents, accounts receivables and accounts payables. Assuming other variables remain the same, a 1% depreciation or appreciation of the TWD against foreign currency as of June 30, 2026 and 2025 would have increased or decreased the net profit after tax by \$1,568 thousand and \$470 thousand, respectively. The analysis is performed on the same basis for both periods.

3) Interest rate risk

The Group's financial assets and financial liabilities with interest rate exposure risk were noted in the liquidity risk section.

The following sensitivity analysis is based on the exposure to the interest rate risk of derivative and non-derivative financial instruments on the reporting date. Regarding liabilities with variable interest rates, the analysis is based on the assumption that the amount of liabilities outstanding at the reporting date was outstanding throughout the year.

If the interest rate increases or decreases by 1%, assuming that all other variables remain constant, the Group's net profit after tax will increase or decrease by \$14,143 thousand and \$8,827 thousand for the six months ended June 30, 2026 and 2025, respectively. The changes are mainly due to floating rate bank deposits and borrowings of the Group.

4) Other price risks

Assuming that the analysis is performed on the same basis for both periods, if equity prices had been 1% higher/lower, pre-tax other comprehensive income for the six months ended June 30, 2026 and 2025 would have increased/decreased by \$7,820 thousand and \$7,038 thousand, respectively, as a result of the changes in fair values of financial assets at fair value through other comprehensive income.

3. Fair value information

1) The categories and fair values of financial instruments

The fair value of financial assets at fair value through profit or loss and financial assets at fair value through other comprehensive income is measured on a recurring basis. The carrying amount and fair value of the Group's financial assets and liabilities, including the information on fair value hierarchy were as follows; however, except as described in the following paragraphs, for financial instruments not measured at fair value whose carrying amount is reasonably close to the fair value, and lease liabilities, disclosure of fair value information is not required:

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2026 AND 2025

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

		June 30, 2026				
		Book value	Fair value			
			Level 1	Level 2	Level 3	Total
Financial assets at fair value through other comprehensive income						
Domestic listed shares	\$	38,105	38,105	-	-	38,105
Foreign listed shares		166,473	166,473	-	-	166,473
Domestic unlisted shares		173,844	-	41,500	132,344	173,844
Foreign unlisted shares		403,571	-	-	403,571	403,571
Accounts receivable		2,965	-	-	-	-
Sub-total		784,958	204,578	41,500	535,915	781,993
Financial assets at amortized cost						
Cash and cash equivalents		3,335,734	-	-	-	-
Time deposits with original maturity of more than 3 months		1,092,135	-	-	-	-
Receivables		6,648,606	-	-	-	-
Guarantee deposits paid		287,931	-	-	-	-
Other financial assets		134,872	-	-	-	-
Sub-total		11,499,278	-	-	-	-
Total		<u>\$ 12,284,236</u>	<u>204,578</u>	<u>41,500</u>	<u>535,915</u>	<u>781,993</u>
Financial liabilities at fair value through profit or loss						
Derivative financial liabilities	\$	315	-	315	-	315
Financial liabilities at amortized cost						
Short-term and long-term borrowings		991,550	-	-	-	-
Payables		4,129,094	-	-	-	-
Guarantee deposits received		54,386	-	-	-	-
Lease liabilities		1,418,738	-	-	-	-
Sub-total		6,593,768	-	-	-	-
Total		<u>\$ 6,594,083</u>	<u>-</u>	<u>315</u>	<u>-</u>	<u>315</u>

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2026 AND 2025

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

	December 31, 2025				
	Book value	Fair value			Total
		Level 1	Level 2	Level 3	
Financial assets at fair value through other comprehensive income					
Domestic listed shares	\$ 2,659	2,659	-	-	2,659
Foreign listed shares	248,855	248,855	-	-	248,855
Domestic unlisted shares	132,312	-	-	132,312	132,312
Foreign unlisted shares	497,648	-	-	497,648	497,648
Accounts receivable	3,581	-	-	-	-
Sub-total	885,055	251,514	-	629,960	881,474
Financial assets at amortized cost					
Cash and cash equivalents	2,847,128	-	-	-	-
Time deposits with original maturity of more than 3 months	612,160	-	-	-	-
Receivables	5,541,911	-	-	-	-
Guarantee deposits paid	282,019	-	-	-	-
Other financial assets	109,646	-	-	-	-
Sub-total	9,392,864	-	-	-	-
Total	<u>\$ 10,277,919</u>	<u>251,514</u>	<u>-</u>	<u>629,960</u>	<u>881,474</u>
Financial liabilities at amortized cost					
Short-term and long-term borrowings	\$ 1,693,221	-	-	-	-
Payables	3,742,683	-	-	-	-
Guarantee deposits received	9,513	-	-	-	-
Lease liabilities	460,685	-	-	-	-
Total	<u>\$ 5,906,102</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>-</u>

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2026 AND 2025

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

	June 30, 2025				
		Fair value			
	Book value	Level 1	Level 2	Level 3	Total
Financial assets at fair value through other comprehensive income					
Domestic listed shares	\$ 2,748	2,748	-	-	2,748
Foreign listed shares	141,448	141,448	-	-	141,448
Domestic unlisted shares	133,622	-	-	133,622	133,622
Foreign unlisted shares	425,948	-	-	425,948	425,948
Sub-total	703,766	144,196	-	559,570	703,766
Financial assets at amortized cost					
Cash and cash equivalents	2,324,907	-	-	-	-
Time deposits with original maturity of more than 3 months	538,340	-	-	-	-
Receivables	6,057,497	-	-	-	-
Guarantee deposits paid	182,911	-	-	-	-
Other financial assets	104,505	-	-	-	-
Sub-total	9,208,160	-	-	-	-
Total	\$ 9,911,926	144,196	-	559,570	703,766
Financial liabilities at fair value through profit or loss					
Derivative financial liabilities	\$ 1,120	-	1,120	-	1,120
Financial liabilities at amortized cost					
Short-term and long-term borrowings	1,172,216	-	-	-	-
Payables	4,678,221	-	-	-	-
Guarantee deposits received	11,124	-	-	-	-
Lease liabilities	467,262	-	-	-	-
Sub-total	6,328,823	-	-	-	-
Total	\$ 6,329,943	-	1,120	-	1,120

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2026 AND 2025

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

2) Valuation techniques for financial instruments not measured at fair value

The Group's valuation techniques and assumptions used for financial instruments not measured at fair value are as follows:

A. Financial assets measured at amortized cost

If the quoted prices in active markets are available, the market price is established as the fair value. However, if quoted prices in active markets are not available, the estimated valuation or prices used by competitors are adopted.

B. Financial liabilities measured at amortized cost

If there is quoted price generated by transactions, the recent transaction price and quoted price data is used as the basis for fair value measurement. However, if no quoted prices are available, the discounted cash flows are used to estimated fair values.

3) Valuation techniques for financial instruments measured at fair value

The Group considers the financial status, operating analysis, most recent transaction price, non-active market quoted price of related equity instrument, and active-market quoted price of similar instrument, and other information, in determining the input value of its investee companies. Periodically updates of information and input value for the valuation model and any necessary adjustments of fair value are required to ensure that the results of estimation are reasonable.

A. Non-derivative financial instruments

If quoted prices in active markets are available, the prices are established as fair values, such as public quoted company stock.

For the Group's financial instruments that have no active markets, the measurement of fair values is listed as follows:

Equity instrument that has no quoted price: The method of comparable Listed Company approach is used to estimate the fair value. The main assumption for the method is to determine the fair value by using the transaction price paid for an identical or a similar instrument of an investee.

B. Derivative financial instruments

Derivative financial instruments are measured by using the common valuation models such as discounted cash flow model and Black-Scholes model.

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2026 AND 2025

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

4) Changes in level 3 of the fair value

	Fair value through other comprehensive income unquoted equity instruments
Balance as of January 1, 2026	\$ 629,960
Total gains and losses recognized	
In other comprehensive income	(93,986)
Reclassification and effect of movements in exchange rates	(59)
Balance as of June 30, 2026	<u><u>\$ 535,915</u></u>
Balance as of January 1, 2025	\$ 532,469
Total gains and losses recognized	
In other comprehensive income	26,959
Reclassification and effect of movements in exchange rates	142
Balance as of June 30, 2025	<u><u>\$ 559,570</u></u>

For the six months ended June 30, 2026 and 2025, the total gains and losses that were included in “unrealized gains and losses from financial assets at fair value through other comprehensive income” were as follows:

	For the Three Months Ended June 30,		For the Six Months Ended June 30,	
	2026	2025	2026	2025
Total gains and losses recognized				
In other comprehensive income, and presented in “unrealized gains and losses from financial assets at fair value through other comprehensive income”	\$ (50,032)	40,924	(93,986)	26,959

5) Quantified information for significant unobservable inputs (level 3) used in fair value measurement

The Group’s financial instruments that use Level 3 inputs to measure fair value include “financial assets at fair value through other comprehensive income— equity investments without active market”.

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2026 AND 2025

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

Quantified information of significant unobservable inputs was as follows:

Item	Valuation techniques	Significant non-observable inputs	The relationship between significant Non-observable inputs and fair value
Financial assets at fair value through other comprehensive income - equity instruments investments without an active market	Market approach- Company comparisons	- P/B Value Multiple (0.669~2.16, 0.746~2.91 and 0.674~2.70 as of June 30, 2026 、 December 31, 2025 and June 30, 2025, respectively.) - Discount due to Lack of Market liquidity (5.31%~30%, 12.93%~30% and 14.06%~30% as of June 30, 2026 、 December 31, 2025 and June 30, 2025, respectively.)	The estimated fair value would increase (decrease) if the value multiple is higher (lower) and the marketability discount is lower (higher)

6) Sensitivity analysis for fair values of financial instruments using Level 3 Inputs

The Group's fair value measurement on financial instruments is reasonable. However, the measurement would differ if different valuation models or valuation parameters are used. For financial instruments using level 3 inputs, if the valuation parameters are changed, the impact on net income or loss and other comprehensive income or loss will be as follows:

			Impact on Fair Value Change on Other Comprehensive income or loss	
	Input	Variation	Favorable Change	Unfavorable Change
June 30, 2026				
Financial assets at fair value through other comprehensive income				
Equity instruments without an active market	Value Multiple	5%	\$ 25,857	(25,857)
Equity instruments without an active market	Discount due to Lack of Market liquidity	5%	35,018	(35,018)
			<u>\$ 60,875</u>	<u>(60,875)</u>
December 31, 2025				
Financial assets at fair value through other comprehensive income				
Equity instruments without an active market	Value Multiple	5%	\$ 30,654	(30,654)
Equity instruments without an active market	Discount due to Lack of Market liquidity	5%	42,391	(42,391)
			<u>\$ 73,045</u>	<u>(73,045)</u>

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2026 AND 2025

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

			Impact on Fair Value Change on Other Comprehensive income or loss	
	Input	Variation	Favorable Change	Unfavorable Change
June 30, 2025				
Financial assets at fair value through other comprehensive income				
Equity instruments without an active market	Value Multiple	5%	\$ 27,199	(27,199)
Equity instruments without an active market	Discount due to Lack of Market liquidity	5%	37,523	(37,523)
			\$ 64,722	(64,722)

(ab) Financial risk management

There were no significant differences of the Group's financial risk management and policies with those disclosed in Note (6)(z) of the consolidated financial statements for the year ended December 31, 2025.

(ac) Capital Management

Management believes that the objectives, policies and processes of capital management of the Group have been applied consistently with those described in the consolidated financial statements for the year ended December 31, 2025. Also, management believes that there were no significant changes in the Group's capital management information as disclosed for the year ended December 31, 2025. Please refer to note (6)(aa) to the consolidated financial statement for the year ended December 31, 2025 for further details.

(ad) Investing and financing activities not affecting current cash flow

The Group's investing and financing activities which did not affect the current cash flow in the six months ended June 30, 2026 and 2025, were as follows:

For acquisitions of right-of-use assets by leasing, please refer to note 6(k).

Reconciliation of liabilities arising from financing activities were as follows:

			Non-cash changes				
			Acquired through a business combination	Acquisition	Foreign exchange movement	Others	
	January 1, 2026	Cash flows					June 30, 2026
Short-term and long-term borrowings	\$ 1,693,221	(701,671)	-	-	-	-	991,550
Lease liabilities	460,685	(87,202)	911,252	144,799	(6,472)	(4,324)	1,418,738
Total liabilities from financing activities	<u>\$ 2,153,906</u>	<u>(788,873)</u>	<u>911,252</u>	<u>144,799</u>	<u>(6,472)</u>	<u>(4,324)</u>	<u>2,410,288</u>

			Non-cash changes				
			Acquired through a business combination	Acquisition	Foreign exchange movement	Others	
	January 1, 2025	Cash flows					June 30, 2025
Short-term and long-term borrowings	\$ 917,531	254,685	-	-	-	-	1,172,216
Lease liabilities	506,170	(67,527)	32,076	32,076	(2,349)	(1,108)	467,262
Total liabilities from financing activities	<u>\$ 1,423,701</u>	<u>187,158</u>	<u>32,076</u>	<u>32,076</u>	<u>(2,349)</u>	<u>(1,108)</u>	<u>1,639,478</u>

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2026 AND 2025

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

(7) Related Party Transactions

(a) Names of related parties and their relationship with related parties

The followings are related parties that have had transactions with the Group during the periods covered in the consolidated financial statements.

<u>Name of related party</u>	<u>Relationship with the Group</u>
Excelsior Investment Co., Ltd.	Entities with significant influence over the Group
Excelsior Group Holdings Co., Ltd.	"
Hsuang Hui Investment Co., Ltd.	"
Bestchain Healthtaiwan Co., Ltd. (Bestchain)	Associate
Excelsior Renal Service Co., Limited (ERS)	"
Asia Best Healthcare Co., Limited (ABH)	"
Medifly Co., Ltd.	"
Medytox Taiwan Inc.	"
Touce Biotech Co., Ltd. (Touce Biotech)	"
Bestsmile Co., Ltd.(Bestsmile)	"
Exceed Healthcare Co., Ltd.	"
NephroCare Limited	"
Cardinal Medical Services Ltd.	"
Asia Best Life Care Co., Ltd. (ABL)	Associate (Note 1)
Excelsior Health Foundation	Other related parties
New Taipei City Hang-An Nursing Home	Other related parties (Note 2)
Ching-Chyuan Hospital Affiliated Nursing Home	"
Xin-Tai General Hospital	"
Jingmei Hospital	"
Ching-Chyuan Hospital	"
Ren Xiang Clinic	"
Xiang Xin Pharmacy	"
Jingmei Hospital Affiliated Home Care	"
Jiayue Home Nursing Center	"
Hu Kang Nursing Home	"
Yuan Lin Ho's Hospital	"

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2026 AND 2025

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

<u>Name of related party</u>	<u>Relationship with the Group</u>
Taipei Zhaoru Nursing and Residential Care Center for the Elderly Operated by Excelsior Long Term Care Corporation Entity under commission from the Department of Social Welfare, Taipei City Government	Other related parties (Note 2)

Note1: Before May 29, 2026, the company was the Group's associate. On May 29, 2026, the Group obtained a majority of the seats on the Board of Directors of the company and consequently obtained control over it.

Note2: Before May 29, 2026, the company was not the Group's related party. On May 29, 2026, the Group obtained a majority of the board seats of Asia Best Life Care, resulting in the company being classified as another related party of the Group.

(b) Significant transactions with related parties

1. Operating revenue

1) Sales revenue

The amounts of significant sales by the Group to related parties were as follows:

	<u>For the Three Months Ended June 30,</u>		<u>For the Six Months Ended June 30,</u>	
	<u>2026</u>	<u>2025</u>	<u>2026</u>	<u>2025</u>
Associate — Bestchain	\$ 663,428	605,856	1,316,166	1,207,651
Associate — ERS	196,010	189,558	386,909	373,136
Associate — Others	42,868	65,544	97,394	130,553
Other related parties	4,744	38	4,744	71
	<u>\$ 907,050</u>	<u>860,996</u>	<u>1,805,213</u>	<u>1,711,411</u>

The aforementioned transactions, except the sales to Bestchain and ERS that were priced on a cost-plus basis, were conducted on normal commercial terms.

2) Repair and maintenance revenue

The amounts of significant repair and maintenance revenue by the Group to related parties were as follows:

	<u>For the Three Months Ended June 30,</u>		<u>For the Six Months Ended June 30,</u>	
	<u>2026</u>	<u>2025</u>	<u>2026</u>	<u>2025</u>
Associate — ERS	\$ 23,219	23,496	46,182	46,514
Associate — Bestchain	1,406	5,479	2,907	8,251
Associate — Others	762	-	762	-
Other related parties	314	-	314	-
	<u>\$ 25,701</u>	<u>28,975</u>	<u>50,165</u>	<u>54,765</u>

There were no significant differences in the terms and pricing offered to related parties compared with those offered to third parties.

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2026 AND 2025

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

3) Other operating revenue-rental revenue

The amounts of significant other operating revenue-rental revenue by the Group to related parties were as follows:

	For the Three Months Ended June 30,		For the Six Months Ended June 30,	
	2026	2025	2026	2025
Entities with significant influence over the Group	\$ 18	18	36	36
Associate — ABH	8,542	10,912	17,083	17,393
Associate — ERS	1,180	1,099	2,265	2,273
Associate — Others	711	729	1,417	5,885
Other related parties — Ching-Chyuan Hospital	12,772	-	12,772	-
Other related parties	6,951	12	6,951	23
	<u>\$ 30,174</u>	<u>12,770</u>	<u>40,524</u>	<u>25,610</u>

The aforementioned transactions, except that the rental amounts were based on mutual agreements, all other terms were based on standard conditions.

4) Other operating revenue-service revenue

The amounts of significant other operating revenue-service revenue by the Group to related parties were as follows:

	For the Three Months Ended June 30,		For the Six Months Ended June 30,	
	2026	2025	2026	2025
Associate	\$ 2,810	3,969	5,827	7,855
Other related parties	292	63	358	125
	<u>\$ 3,102</u>	<u>4,032</u>	<u>6,185</u>	<u>7,980</u>

There were no significant differences in the terms and pricing offered to associates compared with those offered to third parties.

2. Purchases from related parties

The amounts of significant purchases by the Group from related parties were as follows:

	For the Three Months Ended June 30,		For the Six Months Ended June 30,	
	2026	2025	2026	2025
Associate	\$ 36,046	28,082	72,893	82,581
Other related parties	4	-	4	-
	<u>\$ 36,050</u>	<u>28,082</u>	<u>72,897</u>	<u>82,581</u>

There were no significant differences in terms and conditions of the purchases from associates between those provided to the third parties.

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2026 AND 2025

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

3.Receivables from related parties

Receivables from related parties were as follows:

Accounted for as	Category of related party	June 30, 2026	December 31, 2025	June 30, 2025
Notes receivable	Associate	\$ 50	29	54
Other notes receivable	Associate	1,105	916	1,156
Accounts receivable	Associate—Bestchain	698,779	663,255	642,113
Accounts receivable	Associate—ERS	159,894	161,750	152,434
Accounts receivable	Associate—Others	39,349	55,001	56,358
Accounts receivable	Other related parties	22,054	62	125
Other receivables	Associate	5,424	2,097	1,681
Other receivables	Other related parties	1,657	-	-
Guarantee deposits paid	Associate	10,786	-	-
Guarantee deposits paid	Other related parties	10,000	-	-

4.Payables to related parties

Payables to related parties were as follows:

Accounted for as	Category of related party	June 30, 2026	December 31, 2025	June 30, 2025
Accounts payable	Associate	\$ 24,519	24,824	20,883
Accounts payable	Other related parties	4	-	-
Other payables	Associate	19,912	16,053	11,486
Other payables	Other related parties	115	-	-
Deposits received	Associate	7,701	7,891	7,713
Deposits received	Other related parties	3,739	-	-

5.Prepayments

Prepayments to related parties were as follows:

	June 30, 2026	December 31, 2025	June 30, 2025
Associate	\$ -	10,967	15,891
Other related parties	6	-	-
	\$ 6	10,967	15,891

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2026 AND 2025

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

6. Property transactions

1) Purchases of property, plant and equipment

The purchases price of property, plant and equipment purchased from related parties are summarized as follows:

	For the three months ended June 30,		For the Six Months Ended June 30,	
	2026	2025	2026	2025
Associate-Bestsmile	\$ -	6,688	-	6,688
Associate — ERS	-	-	1,209	-
Associate — ABL	-	-	1,607	-
	<u>\$ -</u>	<u>6,688</u>	<u>2,816</u>	<u>6,688</u>

7. Guarantee

As of June 30, 2026, December 31, 2025 and June 30, 2025, the Group provided associates guarantees for loans. The credit limit of the guarantees were \$800,000 thousand, \$1,200,000 thousand and \$800,000 thousand, and the amount utilized were \$400,000 thousand, \$200,000 thousand and \$185,000 thousand, respectively.

8. Capital and Equity

For future planning purposes, the Group increased its investment in Associates - Medytox Taiwan Inc. by NT\$8,000 thousand in 2025, with no change in its ownership percentage after the capital injection.

9. Leases

The Group subleased properties to related parties in 2026 as follows:

For the Six Months Ended June 30, 2026						
Sublessee	Relationship with the Company	Contract Commencement Date	Leased Asset	Total Contract Value	Interest Income	Balances of Lease Payments Receivable
Ching-Chyuan Hospital Affiliated Nursing Home	Other related parties	March 1, 2023	Buildings, Equipment and Superficies	1,181,975	1,435	349,994
Xin-Tai General Hospital	"	December 31, 2023	Equipment	521,677	1,863	291,760
Jingmei Hospital	"	August 1, 2022	Buildings, Equipment and Intangible Assets	176,129	600	75,661
Others	"	January 1, 2021	Buildings, Equipment and Intangible Assets	147,319	530	81,650
Excelsior Renal Service Co., Limited	Associate	January 1, 2023	Buildings and Equipment	99,753	146	55,966

In May 2026, the Group entered into a two-year lease agreement with Bestchain Health Taiwan Co., Ltd., for warehouse premises, with a total contract value of \$99,253 thousand. Interest expense recognized for the three-month period ended June 30, 2026, and for the six-month period ended June 30, 2026, both amounted to \$144 thousand. As of June 30, 2026, lease liabilities amounted to \$90,981 thousand.

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2026 AND 2025

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

10. Others

	For the Three Months Ended June 30,		For the Six Months Ended June 30,	
	2026	2025	2026	2025
<u>Associates and Other related parties</u>				
Other revenue	\$ 555	561	1,342	1,057
Cost of goods sold	(2,011)	(1,916)	(3,136)	(6,482)
Repair and maintenance costs	(950)	(3,790)	(1,439)	(4,828)
Fright and warehousing expense	(13,348)	(13,243)	(26,557)	(26,323)
Rent expense	(462)	(993)	(914)	(2,378)
Other expense	(8,233)	(7,611)	(16,633)	(15,055)

The aforementioned rentals collected or paid quarterly or monthly were based on prevailing market rates.

As of June 30, 2026, December 31, 2025 and June 30, 2025, the Group had received collections in advance from associates for \$2,591 thousand, \$1,292 thousand and \$1,464 thousand, respectively.

(c) Key management personnel compensation

Key management personnel compensation comprised:

	For the Three Months Ended June 30,		For the Six Months Ended June 30,	
	2026	2025	2026	2025
Short-term employee benefits \$	26,192	17,785	48,133	39,710
Post-employment benefit	363	251	539	502
Share-based payment	-	-	9,761	-
\$	26,555	18,036	58,433	40,212

(8) Pledged Assets

The carrying amount of pledged assets were as follows:

Pledged assets	Object	June 30, 2026	December 31, 2025	June 30, 2025
Current deposits and time deposits	Bank loans, bank guarantee and credit card document receiving service guarantee	\$ 148,327	109,646	102,767
Notes receivable and other notes receivable	Guarantee of short-term loan or strengthening credit	234,479	197,298	287,361
Property, plant and equipment	Bank loans	97,909	99,403	88,907
Investment property	"	1,345,371	1,346,530	1,350,757
Refundable deposits (Recognized in other non-current financial assets)	Guarantees for sales performance, deposits and lease deposits, etc.	278,472	282,019	182,911
		\$ 2,104,558	2,034,896	2,012,703

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2026 AND 2025

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

(9) Significant Commitments and Contingencies

(a) Unrecognized contractual commitments

1. As of June 30, 2026, December 31, 2025 and June 30, 2025, the unused letters of credit were \$66,948 thousand, \$54,634 thousand and \$52,748 thousand, respectively. The guarantee letters issued by banks for sales contract guarantee and purchase bid of hospital were \$918,453 thousand, \$1,054,975 thousand and \$888,080 thousand, respectively.
2. In April 2022, the Company entered into a supply agreement with the Hong Kong-based company. Pursuant to the agreement, the Company shall purchase certain products from the Hong Kong-based company in agreed quantities at agreed prices annually.
3. The Group won the bid for the procurement project for COVID-19 treatment drugs (including storage and distribution) from the Centers for Disease Control, Ministry of Health and Welfare (CDC), who entered into an agreement with the Group on July 17, 2024, in which the Group will purchase drugs and provide storage and distribution services to the CDC.

(10) Losses due to Major Disasters : None.

(11) Subsequent Events : None.

(12) Other

- (a)** The employee benefits, depreciation, depletion and amortization expenses categorized by function were as follows:

By item	By function	For the Three Months Ended June 30, 2026			For the Three Months Ended June 30, 2025		
		Operating cost	Operating expense	Total	Operating cost	Operating expense	Total
Employee benefits							
Salary		105,899	125,243	231,142	77,126	123,347	200,473
Labor and health insurance		9,905	12,267	22,172	7,320	10,457	17,777
Pension		5,201	2,980	8,181	3,666	5,741	9,407
Others		5,480	7,329	12,809	3,330	6,248	9,578
Depreciation		61,569	27,686	89,255	56,677	20,144	76,821
Amortization		14	2,227	2,241	129	1,686	1,815

By item	By function	For the Six Months Ended June 30, 2026			For the Six Months Ended June 30, 2025		
		Operating cost	Operating expense	Total	Operating cost	Operating expense	Total
Employee benefits							
Salary		187,092	279,089	466,181	148,049	260,943	408,992
Labor and health insurance		18,004	25,130	43,134	14,971	22,468	37,439
Pension		9,160	9,231	18,391	7,233	11,557	18,790
Others		9,286	14,354	23,640	7,062	12,489	19,551
Depreciation		112,522	49,047	161,569	113,610	38,704	152,314
Amortization		24	4,304	4,328	303	3,298	3,601

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2026 AND 2025

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

(13) Other disclosures

(a) Information on significant transactions

The following is the information on significant transactions required by the “Regulations Governing the Preparation of Financial Reports by Securities Issuers” for the Group for the six months ended June 30, 2026:

1. Fund financing to other parties: None.
2. Guarantees and endorsements for other parties:

(Expressed in thousands of New Taiwan dollars)

No.	Endorsement/ guarantee provider	Counter-party		Limitation on endorsement /guarantee amount provided to each guaranteed party	Maximum balance for the year	Ending balance	Amount actually drawn	Amount of endorsement/ guarantee collateralized by properties	Ratio of accumulated endorsement/guar- antee to net equity per latest financial statements	Maximum endorsement guarantee amount allowance (Note 7)	Guarantee provided by parent company	Guarantee provided by a subsidiary	Guarantee provided to subsidiaries in Mainland China
		Name	Nature of relationship (Note 2)										
0	The Company	Excelsior Asset Management CO., Ltd. (Note 4)	2	1,962,698	990,000	570,000	-	-	5.81 %	9,813,491	Y	N	N
0	"	EG Healthcare, Inc. (Note 4)	2	1,962,698	243,040	243,040	-	-	2.48 %	9,813,491	Y	N	N
0	"	Renal Laboratories Sdn. Bhd. (Note 4)	2	1,962,698	80,028	79,625	37,773	-	0.81 %	9,813,491	Y	N	N
0	"	Medi-Chem System Sdn. Bhd. (Note 4)	2	1,962,698	16,005	15,925	3,777	-	0.16 %	9,813,491	Y	N	N
0	"	Bestchain Healthtaiwan Co., Ltd. (Note 3)	1	2,464,263	1,200,000	800,000	400,000	-	8.15 %	9,813,491	N	N	N
1	Dynamic Medical Technologies Inc.	CYJ International Taiwan Inc. (Note 5)	2	315,904	100,000	100,000	-	-	6.33 %	789,759	Y	N	N
2	Arich Best Chain Co., Ltd.	Arich Enterprise Co., Ltd. (Note 6)	3	9,432	-	-	-	-	- %	15,721	N	Y	N

Note 1: the description of number column:

1. 0 is issuer.
2. Investees are listed by name and numbered starting with 1.

Note 2: Relationship with the Company

1. The companies with which it has business relations.
2. Subsidiaries in which the Company directly or indirectly holds more than 50% of its total outstanding common shares.
3. The parent company which directly or indirectly holds more than 50% of its voting rights.
4. Subsidiaries in which the Company directly or indirectly holds more than 90% of its voting rights.
5. Companies in the same type of business and providing mutual endorsements/ guarantees in favor of each other in accordance with the contractual obligations in order to fulfill the needs of the construction project.
6. Shareholders making endorsements and/or guarantees for their mutually invested company in proportion to their shareholding percentage.
7. Companies in the same type of business providing guarantees of pre-sale contracts according to the regulation.

Note 3: For guarantee and endorsement to those companies with business contact, the maximum amount cannot exceed the trading amount between two parties for the current year.

Note 4: The total amount of guarantee and endorsement cannot exceed 20% of the Company's net asset value from the most recent audited or reviewed report.

Note 5: The total amount of guarantee and endorsement cannot exceed 20% of Dynamic's net asset value from the most recent audited or reviewed report.

Note 6: The total amount of guarantee and endorsement cannot exceed 30% of Arich Best Chain's net asset value from the most recent audited or reviewed report.

Note 7: The total amount of guarantee and endorsement cannot exceed the Company's net asset value from the most recent audited or review report: Dynamic and Arich Best Chain cannot exceed 50% of its net asset value from the most recent audited or reviewed report.

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2026 AND 2025

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

3. Information regarding material securities held at the reporting date (subsidiaries, associates and joint ventures not included):

(Expressed in thousands of New Taiwan dollars)

Name of holder	Category and name of security	Relationship with the Company	Account title	Ending balance				Notes
				Number of shares	Book value	Percentage of shares	Market value	
The Company	3-D Matrix, Ltd.	-	Fair value through other comprehensive income	273,400	19,834	0.21 %	19,834	
"	Gie Cheng Co., Ltd.	-	"	3,795,000	32,827	17.25 %	32,827	
"	Rui Guang Healthcare Co., Ltd.	-	"	2,423,951	29,427	7.15 %	29,427	
"	Sunder Biomedical Tech. Co., Ltd.	-	"	2,279,578	51,199	3.80 %	51,199	
"	Linkon International Golf & Country Club	-	"	1	16,550	0.10 %	16,550	
"	Chi Sheng Pharma & Biotech Co., Ltd.	-	"	1,272,300	38,105	2.13 %	38,105	
"	Anxo Pharmaceutical Co., Ltd.	-	"	2,500,000	41,500	4.46 %	41,500	
Excelsior Healthcare Co. Limited	Chai Tai Bo Ai Investment Limited	-	"	10,000	-	8.00 %	-	
EG Healthcare, Inc.	The Orchard Golf & Country Club	-	"	1	2,025	- %	2,025	
Dynamic Medical Technologies Inc.	Caregen Co., Ltd.	-	"	102,816	146,639	0.19 %	146,639	
Excelsior Beauty Co., Ltd.	Join Fun Co., Ltd.	-	"	263,340	2,341	19.00 %	2,341	
Arich Enterprise Co., Ltd.	National Pharmaceutical Logistics Corp., Ltd.	Board director of investee	"	-	401,546	17.65 %	401,546	Note

Note : Act as limited company, no outstanding share.

4. Information regarding related-party purchases and/or sales exceeding 100 million or 20% of the Company's paid-in capital:

(Expressed in thousands of New Taiwan dollars)

Name of company	Name of Counter-party	Relationship	Transaction details				Transactions with terms different from others		Account/note receivable (payable)		Notes
			Purchase/Sale	Amount	Percentage of total purchases/sales	Credit period	Unit price	Credit period	Balance	Percentage of total accounts/notes receivable (payable)	
The Company	Excelsior Renal Service Co., Limited	Associates	Sales	386,881	(14.05)%	Net 30-60 days	-		159,867	12.11 %	Note 1
"	Bestchain Healthtaiwan Co., Ltd.	"	"	1,315,728	(47.79)%	Net 30-90 days	-		698,477	52.92 %	Note 1
"	EG Healthcare, Inc.	Subsidiary	"	121,578	(4.42)%	Net 90 days	-		54,284	4.11 %	Note 1

Note 1: The unit price of cost of goods sold for the Company is based on cost-plus pricing approach by product that is lower than average; because, the expense of goods sold for related parties is lower than average price as well.

5. Information regarding receivables from related parties exceeding 100 million or 20% of the Company's paid-in capital:

(Expressed in thousands of New Taiwan dollars)

Name of related party	Counter-party	Relationship	Balance of receivables from related party	Turnover rate	Past-due receivables from related party		Subsequently received amount of receivables from related party	Allowances for bad debts
					Amount	Action taken		
The Company	Excelsior Renal Service Co., Limited	Associates	159,867	4.81	-	-	65,059	-
"	Bestchain Healthtaiwan Co., Ltd.	"	698,477	3.87	-	-	-	-

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2026 AND 2025

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

6. Significant transactions and business relationship between the parent company and its subsidiaries for the six months ended June 30, 2026:

Number	Name of the company	Name of the counter-party	Existing relationship with the counter-party	Transaction details during 2026			
				Account name	Amount	Terms of trading	Percentage of the total consolidated revenue or total assets
0	The Company	EG Healthcare, Inc.	1	Sales	121,578	Usual terms and conditions	2.57 %
"	"	"	1	Account Receivable	54,284	The same as the term for other general trading partners	0.26 %
1	Dynamic Medical Technologies Inc.	Excelsior Beauty Co., Ltd.	3	Sales	13,807	The same as the term for other general trading partners	0.29 %
"	"	CYJ International Taiwan Inc.	3	Account Receivable	44,928	The same as the term for other general trading partners	0.21 %
"	"	"	3	Sales	36,036	The same as the term for other general trading partners	0.76 %

Note 1: The numbers denote the following:

1. 0 represents the Company.
2. Subsidiaries are listed by names and numbered starting with 1.

Note 2: Relationship with the listed companies:

1. The Company to subsidiary
2. Subsidiary to the Company
3. Subsidiary to subsidiary

Note 3: The transaction amount is calculated as a proportion of the consolidated revenue or assets. If categorized as an asset or liability, the calculation is compared with the consolidated assets; if categorized as income or loss, the calculation is compared with the consolidated income or loss.

Note 4: The aforementioned inter-company transactions have been eliminated in the consolidated financial statements.

(b) Information on investees:

For the six months ended June 30, 2026, the following is the information of investees (excluding investees in Mainland china):

(Amounts Expressed in Thousands of New Taiwan Dollars, Except for Share Data)

Name of the investor	Name of investee	Location	Major operations	Initial investment amount		Ending balance			Net income (loss) of the investee	Investment income (losses)	Notes
				Ending balance	Beginning balance	Shares	Ratio of shares	Book value			
The Company	Bestchain Healthtaiwan Co., Ltd.	New Taipei City	Sale of medical equipment and medicines, interagation of warehousing and information	299,024	299,024	65,730,352	44.71 %	1,081,317	131,224	58,629	Associates (Note 1)
"	Arich Enterprise Co., Ltd.	New Taipei City	Sale of medicines, and logistics service	380,856	380,856	29,829,742	40.00 %	754,152	30,975	12,390	Subsidiary (Note 2)
"	Dynamic Medical Technologies Inc.	New Taipei City	Sale, maintenance and lease of laser medical equipment for beauty treatment, and sale of consumables of beauty treatment and cosmetic products	116,131	116,131	13,563,450	33.97 %	547,561	73,108	24,833	Subsidiary
"	Excelsior Healthcare Co., Limited	British Virgin Islands	Investment business	898,782	898,782	28,695,856	100.00 %	1,792,448	158,242	158,242	Subsidiary
"	Sunrise Health Care Company	New Taipei City	Sale of medical equipment, and medical management consultancy service	18,806	18,806	2,085,547	20.86 %	28,255	621	129	Associates
"	Excelsior Medical (HK) Co., Limited	Hong Kong	Investment business	963,137	963,137	33,807,013	64.36 %	1,238,159	68,888	44,336	Subsidiary

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2026 AND 2025

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

Name of the investor	Name of investee	Location	Major operations	Initial investment amount		Ending balance			Net income (loss) of the investee	Investment income (losses)	Notes
				Ending balance	Beginning balance	Shares	Ratio of shares	Book value			
The Company	Excelsior Beauty Co., Ltd.	New Taipei City	Sales of lifestyle beauty products and treatments, and sales of medical beauty products	28,543	28,543	5,190,662	41.02 %	102,001	22,959	9,417	Sub-subsidiary
"	Excelsior Asset Management Co., Ltd.	New Taipei City	Sales of medical equipment, precision instrument and real estate	780,525	780,525	87,375,600	100.00 %	734,596	17,279	17,279	Subsidiary
"	Medifly Co., Ltd.	Taichung	Sale of medical equipment and medicines	31,899	31,899	3,615,976	28.66 %	107,438	21,517	6,167	Associates
"	Asia Best Life Care Co., Ltd	New Taipei City	Long-term care business, rental and leasing services, medical consumables sales and information services	953,836	953,836	84,633,340	49.02 %	1,135,792	59,309	29,075	Subsidiary
Excelsior Healthcare Co., Limited	EG Healthcare, Inc.	Philippines	Sale and lease of medical equipment, and medical management consultancy service	82,166	19,256	21,156,430	99.99 %	261,589	47,331	-	Sub-subsidiary (Note 3)
"	Excelsior Renal Service Co., Limited	Hong Kong	Sale, maintenance and lease of medical equipment, and medical management consultancy service	312,505	312,505	73,375,728	49.00 %	408,615	167,729	-	Associates
"	Excelsior Medical (HK) Co., Limited	Hong Kong	Investment business	516,071	516,071	18,724,062	35.64 %	685,640	68,888	-	Subsidiary
"	Excelsior Investment (Malaysia) Co., Ltd	British Virgin Islands	Investment business	343,026	343,026	11,171,272	100.00 %	323,631	(1,887)	-	Sub-subsidiary
Dynamic Medical Technologies Inc.	Dynamic Medical Technologies (Hong Kong) Ltd.	Hong Kong	Sale of cosmetic health-care products	104,652	104,652	13,061,783	100.00 %	58,405	(1,069)	-	Sub-subsidiary
"	Excelsior Beauty Co., Ltd.	New Taipei City	Sales of lifestyle beauty products and treatments, and sales of medical beauty products	55,395	55,395	6,819,523	53.89 %	103,167	22,959	-	Sub-subsidiary (Note 1)
"	CYJ International Taiwan Inc.	New Taipei City	Sales of lifestyle beauty products and treatments, and sales of medical beauty products	155,709	155,709	13,851,588	55.41 %	136,655	(3,658)	-	Sub-subsidiary
"	Medytox Taiwan Inc.	Taipei City	Sale of cosmetic health-care products	26,000	26,000	2,600,000	40.00 %	7,770	3,151	-	Associates
"	TOUCE BIOTECH Co., Ltd	New Taipei City	Sale of cosmetic health-care products	45,000	45,000	420,000	35.00 %	45,859	1,567	-	Associates
Arich Enterprise Co., Ltd.	Arich Best Chain Co., Ltd.	New Taipei City	Logistics Business	31,080	31,080	3,000,000	100.00 %	31,655	452	-	Sub-subsidiary
Excelsior Medical (HK) Co., Limited	Asia Best Healthcare Co., Ltd.	Cayman Islands	Healthcare management services	458,902	458,902	129,492	48.47 %	666,787	44,184	-	Associates
"	Cardinal Medical Services Ltd.	British Virgin Islands	Sale of medical equipment, and medical management consultancy service	106,121	106,121	9,800	49.00 %	111,426	45,319	-	Associates

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2026 AND 2025

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

Name of the investor	Name of investee	Location	Major operations	Initial investment amount		Ending balance			Net income (loss) of the investee	Investment income (losses)	Notes
				Ending balance	Beginning balance	Shares	Ratio of shares	Book value			
Excelsior Medical (HK) Co., Limited	NephroCare Limited	Hong Kong	Sale of medical equipment, and medical management consultancy service	688,755	688,755	151,801,588	49.00 %	681,845	37,666	-	Associates
Excelsior Investment (Malaysia) Co., Ltd	Renal Laboratories Sdn. Bhd.	Malaysia	Manufacture of medical equipment	288,387	288,387	32,523,586	81.90 %	276,617	(2,653)	-	Sub-subsidiary
"	Medi-Chem Systems Sdn. Bhd.	Malaysia	Sale of medical equipment	44,052	44,052	350,000	70.00 %	42,035	1,441	-	Sub-subsidiary
Medi-Chem Systems Sdn. Bhd.	Renal Management Sdn. Bhd.	Malaysia	Lease business	1,315	1,315	200,000	100.00 %	9,723	69	-	Sub-subsidiary
Asia Best Life Care Co., Ltd	Excelsior Long Term Care Corporation Entity	New Taipei City	Long-term care and rehabilitation services	123,849	123,849	-	99.00 %	152,984	15,350	-	Sub-subsidiary
"	Excelsior N Long Term Care Corporation	New Taipei City	Long-term care and rehabilitation services	193,050	193,050	-	99.00 %	137,848	(4,134)	-	Sub-subsidiary
"	Anxin Nice Care Co., Ltd.	New Taipei City	Home-based service business	50,000	50,000	5,000,000	100.00 %	27,225	(1,654)	-	Sub-subsidiary
Anxin Nice Care Co., Ltd.	Fengxuan International Business Co., Ltd.	New Taipei City	Home-based service business	4,800	4,800	-	100.00 %	4,972	754	-	Sub-subsidiary
"	LiJi Long Term Care Intergration Technology Co., Ltd.	New Taipei City	Home-based service business	4,960	4,960	50,000	100.00 %	5,209	(3)	-	Sub-subsidiary
"	Shi Wang Life Co., Ltd.	New Taipei City	Home-based service business	2,598	2,598	-	100.00 %	2,507	(257)	-	Sub-subsidiary

Note 1: Including the adjustment made from the unrealized gain/loss with subsidiaries and associates.

Note 2: Including the amortization listed by the book value of net identified assets.

Note 3: On November 25, 2025, the Board of Directors of EG Healthcare, Inc. approved a cash capital increase of 11,728,941 shares, at an issue price of USD 2,000 thousand per share. Following the capital increase, which were fully subscribed by the Group. This capital increase has been changed on March 27, 2026.

Note 4: The aforementioned inter-company transactions have been eliminated in the consolidated financial statements.

(c) Information on investment in Mainland China:

1. Information on investment in Mainland China:

(Amounts Expressed in Thousands of New Taiwan Dollars)

Name of the investee	Main Businesses and products	Total amount of paid-in capital	Method of investment (Note 1)	Accumulated outflow of investment from Taiwan as of January 1, 2026	Investment flows		Accumulated outflow of investment from Taiwan as of June 30, 2026	Net income (loss) of the investee	Direct /indirect shareholding (%) by the Company	Current investment gains and losses	Carrying Amount	Accumulated Inward Remittance of Earnings
					Out-flow	Inflow						
Excelsior Healthcare (Shanghai) Corporation (Note 3)	Sale and lease of medical equipment, and medical management consultancy service	-	(2)	30,240	-	-	30,240	-	- %	-	-	-
Shanghai Lintech Medicare Co. (Note 4)	Sale and maintenance of medical equipment	-	(2)	29,213	-	-	29,213	-	- %	-	-	-
Pacific Beijing Bo-Ai Medical Management Consulting Co., Ltd.	Investment business and medical management consultancy service	84,187	(2)	80,327	-	-	80,327	58	7.80 %	-	-	-
SinoExcelsior Investment Inc. (Note 5, 7)	Sale of medical equipment, and medical management consultancy service	179,004	(2)	947,845	-	-	947,845	(325)	100.00 %	(325)	31,311	-
Guangzhou Dynamic Inc.	Sale and maintenance of medical equipment	44,346	(2)	119,574	-	-	119,574	(603)	100.00 %	(603)	6,805	-
Beijing Dynamic Inc. (Note 6)	Sale and maintenance of medical equipment	-	(2)	7,101	-	-	7,101	-	- %	-	-	-

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2026 AND 2025

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

Name of the investee	Main Businesses and products	Total amount of paid-in capital	Method of investment (Note 1)	Accumulated outflow of investment from Taiwan as of January 1, 2026	Investment flows		Accumulated outflow of investment from Taiwan as of June 30, 2026	Net income (loss) of the investee	Direct /indirect shareholding (%) by the Company	Current investment gains and losses	Carrying Amount	Accumulated Inward Remittance of Earnings
					Out-flow	Inflow						
National Pharmaceutical Logistics Corp., Ltd.	Medical logistics	370,493	(3)	66,603	-	-	66,603	36,129	17.65 %	-	401,546	98,061

2. Limitation on investment in Mainland China:

Company	Accumulated Investment in Mainland China as of December 31, 2026	Investment Amounts Authorized by Investment Commission, MOEA	Upper Limit on Investment (Note 8)
The Company	1,087,625	1,289,640	5,888,095
Dynamic Medical Technologies Inc.	126,675	126,675	947,711
Arich Enterprise Co., Ltd.	66,603	66,603	1,134,417

Note 1: Investments in Mainland China are differentiated by the following four methods:

- (1) Direct investment in Mainland China with remittance through a third region.
- (2) Indirect investment in Mainland China through an existing investee company in a third region.
- (3) Other methods (i.e. entrusted Investment)

Note 2: Recognition of investment gain or loss during current period is pursuant to the following:

- (1) If the corporation is in the set-up phase, notes are required.
- (2) Recognition basis of investment gains or losses is determined by the following three types, and related notes are required.
 - 1) Financial statements of the investee company were audited and certified by an international firm in cooperation with an R.O.C. accounting firm.
 - 2) Financial statements of the investee company were audited and certified by the external accountant of the parent company.
 - 3) Others

Note 3: The liquidation procedure of Excelsior Healthcare (Shanghai) Corporation was completed in March 2016, and the investment had remitted to Excelsior Healthcare Co., Limited in the third place. As of June 30, 2026, the accumulated amount of investment from Taiwan has not been repatriated yet.

Note 4: The disposal of Shanghai Lintech Medicare Co. was completed in December 2015. As of June 30, 2026, the original investment amount of \$29,213 thousand from Taiwan has not been repatriated yet.

Note 5: The current investment outflow is not included the direct investment amount of \$207,380 thousand through the third region.

Note 6: The liquidation, with the deductible amount of USD 826 thousand, had been completed in November 2018, and the Investment Commission's authorization letter was obtained on April 10, 2025.

Note 7: Based on a resolution approved during its board meeting held on December 18, 2024, Sino Excelsior Investment Inc. conducted a cash capital reduction of CNY25,000 thousand, at a ratio of 42% with the approval of the competent authority on February 6, 2025. The fund had been remitted to Excelsior Medical (HK) Co., Ltd., belonging to a third region. As of June 30, 2026, the accumulated amount of investment from Taiwan has not yet to be repatriated.

Note 8: (1) The upper limit on investment of the Company and Dynamic is the 60% of net value.

(2) The upper limit on investment of Arich is the higher of \$80,000 thousand or 60% of net value.

Note 9: All amounts listed are disclosed in NTD.

3. Significant transactions :

The significant inter-company transactions with the subsidiary in Mainland China, which were eliminated in the preparation of consolidated financial statements, are disclosed in "Information of significant transactions".

(14) Segment Information

Information reported to the chief operating decision maker for the purpose of resource allocation and assessment of segment performance focuses on the types of company. Specifically, the Group's reportable segments were as follows:

- (a) Excelsior segment - the Company.
- (b) Dynamic segment - Dynamic, Hong Kong Dynamic, Excelsior Beauty, Guangzhou Dynamic, and CYJ International Taiwan Inc..
- (c) Arich segment - Arich , and Arich Best Chain.

(ENGLISH TRANSLATION OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN CHINESE)

EXCELSIOR MEDICAL CO., LTD. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2026 AND 2025

(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, UNLESS OTHERWISE SPECIFIED)

- (d) Asia Best Life Care segment - Anxin Nice Care, Fengxuan, LiJi, Shi Wang, Excelsior Long Term Care, and Excelsior N Long Term Care Corporation.
- (e) Other segment - Bestsmile, Excelsior Healthcare, EG Healthcare, Excelsior Investment (Malaysia), Renal Laboratories Sdn. Bhd., Medi-Chem Systems Sdn. Bhd., Renal Management Sdn. Bhd., Excelsior Asset, Hong Kong Excelsior, and SinoExcelsior Investment.

The Group's operating segment information and reconciliation are as follows:

For the Three Months Ended June 30, 2026	Excelsior segment	Dynamic segment	Arich segment	Asia Best Life Care Co., Ltd.	Others	Adjustment and Elimination	Total
Revenue							
Revenue from external customers	\$ 1,369,770	343,379	376,229	75,864	221,002	-	2,386,244
Inter-segment revenue	68,462	1,018	-	(388)	17,383	(86,475)	-
Total	\$ 1,438,232	344,397	376,229	75,476	238,385	(86,475)	2,386,244
Reportable segment profit (loss)	\$ 357,317	57,720	13,999	6,474	127,750	(145,289)	417,971
For the Three Months Ended June 30, 2025							
Revenue							
Revenue from external customers	\$ 1,314,188	327,119	378,713	-	147,629	-	2,167,649
Inter-segment revenue	26,505	100	-	-	4,883	(31,488)	-
Total	\$ 1,340,693	327,219	378,713	-	152,512	(31,488)	2,167,649
Reportable segment profit (loss)	\$ 262,327	54,424	38,532	-	99,257	(122,417)	332,123
For the Six Months Ended June 30, 2026							
Revenue							
Revenue from external customers	\$ 2,747,197	684,036	787,610	75,864	434,495	-	4,729,202
Inter-segment revenue	127,862	3,137	-	(388)	50,543	(181,154)	-
Total	\$ 2,875,059	687,173	787,610	75,476	485,038	(181,154)	4,729,202
Reportable segment profit (loss)	\$ 597,343	102,182	37,263	6,474	237,344	(268,699)	711,907
For the Six Months Ended June 30, 2025							
Revenue							
Revenue from external customers	\$ 2,583,522	678,197	772,514	-	282,741	-	4,316,974
Inter-segment revenue	63,912	257	-	-	17,325	(81,494)	-
Total	\$ 2,647,434	678,454	772,514	-	300,066	(81,494)	4,316,974
Reportable segment profit (loss)	\$ 488,994	112,797	74,122	-	187,957	(234,476)	629,394